

This item is the archived peer-reviewed author-version of:

Reviewing the variability in urinary concentrations of non-persistent organic chemicals : evaluation across classes, sampling strategies and dilution corrections

Reference:

Roggeman Maarten, Gys Celine, Klimowska Anna, Bastiaensen Michiel, Wielgomas Bartosz, Ait Bamai Yu, Covaci Adrian.- Reviewing the variability in urinary concentrations of non-persistent organic chemicals : evaluation across classes, sampling strategies and dilution corrections
Environmental research - ISSN 1096-0953 - 215:2(2022), 114332
Full text (Publisher's DOI): <https://doi.org/10.1016/J.ENVRES.2022.114332>
To cite this reference: <https://hdl.handle.net/10067/1902180151162165141>

1 **Reviewing the variability in urinary concentrations of non-persistent organic chemicals:**
2 **evaluation across classes, sampling strategies and dilution corrections**

3
4 Maarten Roggeman¹, Celine Gys¹, Anna Klimowska^{1,2},
5 Michiel Bastiaensen¹, Bartosz Wielgomas², Yu Ait Bamai^{1,3}, Adrian Covaci^{1*}

6
7 ¹Toxicological Center, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium

8 ² Department of Toxicology, Medical University of Gdańsk, Al. Gen. Hallera 107, 80-416 Gdańsk, Poland

9 ³ Hokkaido University Center for Environmental and Health Sciences, Kita 12, Nishi 7, Kita-ku Sapporo 060-
10 0812, Japan

11
12 *Corresponding author: Adrian Covaci

13 Toxicological Center, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium

14 E-mail: adrian.covaci@uantwerpen.be

15

16 **Abstract**

17 Various biomonitoring studies have been carried out to investigate the exposure of populations by measuring
18 non-persistent organic chemicals in urine. To accurately assess the exposure, study designs should be
19 carefully developed to maximise reproducibility and achieve good characterization of the temporal
20 variability. To test these parameters, the intraclass correlation coefficients (ICCs) are calculated from
21 repeated measurements and range from poor (<0.4) to excellent (≥ 0.75). Several studies have reported ICCs
22 based on diverse study designs, but an overview, including recommendations for future studies, was lacking.
23 Therefore, this review aimed to collect studies describing ICCs of non-persistent organic chemicals, discuss
24 variations due to study design and formulate recommendations for future studies. More than 60 studies
25 were selected, considering various chemical classes: bisphenols, pyrethroids, parabens, phthalates,
26 alternative plasticizers and phosphate flame retardants. The variation in ICCs for an individual chemical was
27 high (e.g. ICC of propyl paraben = 0.28 - 0.91), showing the large impact of the study design and of the specific
28 exposure sources. The highest ICCs were reported for parabens (median = 0.52), while lowest ICCs were for
29 3-phenoxybenzoic acid (median = 0.08) and bisphenol A (median = 0.20). Overall, chemicals that had an
30 exposure source with high variation, such as the diet, showed lower ICCs than those with more stable
31 exposure sources, such as indoor materials. Urine correction by specific gravity had an overall positive effect
32 on reducing the variability of ICCs. However, this effect was mostly seen in the adult population, while specific
33 compounds showed less variation with creatinine correction. Single samples might not accurately capture
34 the exposure to most non-persistent organic chemicals, especially when small populations are sampled.
35 Future studies that examine compounds with low ICCs should take adequate measures to improve accuracy,
36 such as correcting dilution with specific gravity or collecting multiple samples for one participant.

37

38 **Keywords**

39 Human biomonitoring; intraclass correlation coefficient; urine; temporal variability; emerging contaminants;

40

41 **1. Introduction**

42 During the past decades, many new chemicals have been introduced into our environment and consumer
43 products, such as alternatives to older, more persistent and sometimes regulated compounds. Brominated
44 flame retardants were substituted by organophosphates, bisphenol A (BPA) was replaced by alternative
45 bisphenols and phthalates were swapped for newer plasticizers. Humans are exposed to these emerging
46 contaminants via various sources, such as air and dust from the indoor environment, food, consumer
47 products and medical devices. Biomonitoring of these chemicals in human biological matrices is a valuable
48 tool to assess internal exposure and potential health risks. Many of these emerging compounds are more
49 polar and less metabolically stable and thus less persistent than their older counterparts, resulting in shorter
50 biological half-lives and substantial variability in their urinary levels, within and between individuals and
51 within and across days. Consequently, urinary concentrations of these emerging chemicals or their
52 metabolites captured through spot sampling likely reflect only recent exposure (Aylward et al., 2014; Aylward
53 et al., 2017; Christiansen et al. 2012; Preau et al., 2010). Environmental exposure to chemicals is constantly
54 changing, causing difficulties in reliably determining total exposure, referred to as the exposome.
55 Understanding the variability in the exposure patterns is crucial to establish time-dependent relationships
56 between exposome and health outcomes, which require rigorous and well-designed studies. When
57 characterizing the individual exposome, the biological half-life of a chemical is an important factor that
58 contributes to the variation in exposure level across time and location. Therefore, determining the variability
59 of exposure over time, considering relevant windows of susceptibility at different stages of life and
60 establishing a sufficient sample size are critical topics to investigate in order to obtain reproducible results
61 (Buck Louis et al., 2019; Chung et al., 2019).

62 Given the ever-rising number of emerging contaminants humans are exposed to, biomonitoring
63 studies are frequently and increasingly carried out to characterize potential risks to human health. In order
64 to correctly perform risk assessment, it is important that exposure to these relatively new chemicals is
65 accurately characterized. Because of the properties of many of these emerging contaminants, in particular
66 the short half-lives), the study design, together with the resulting sampling campaigns and the number of
67 participants, are of increasing importance to adequately extrapolate the internal human exposure to a
68 broader population. In this context, a single spot (urine) sample, as is common in traditional biomonitoring
69 campaigns, might not be representative to characterize the exposure of an individual. Recently, various
70 efforts have been made to evaluate the reproducibility of biomonitoring measurements (Bastiaensen et al.,
71 2020b; Gys et al., 2021b; Klimowska et al., 2020) or to estimate how many samples are needed per individual
72 to obtain an accurate exposure assessment (Faÿs et al., 2020). However, a clear conclusion on this matter
73 and suggestions for improvement of study design in the future are missing. Furthermore, it is not always
74 feasible to collect human biological samples at multiple times in an epidemiological setting and to repeatedly
75 analyse biomarkers of exposure in a large number of study participants.

76 The reproducibility of repeated measurements for non-persistent contaminants is often evaluated
77 through the intraclass correlation coefficient (ICC), a frequently used statistical and non-dimensional
78 parameter. ICC is composed of various components and is mathematically computed as the ratio of the
79 between-individual variance to the total variance (i.e., the sum of the between- and within-individual
80 variance components). The equation to calculate the ICC is as follows:

$$81 \quad ICC = \frac{\sigma^2_{between\ indiv.}}{\sigma^2_{total}} = \frac{\sigma^2_{between\ indiv.}}{\sigma^2_{withi\ indiv.\ between\ day} + \sigma^2_{within\ indiv.\ within\ day} + \sigma^2_{between\ indiv.}}$$

83
84 A visual representation of the various components that contribute to the ICC value is presented in
85 Figure 1. ICCs can range from zero (indicating low reproducibility over time) to one (indicating
86 high reproducibility and less variability). The reproducibility of measurements, which ultimately is closely
87 related to the ICCs, is usually categorized as poor (<0.40), fair to good (0.40 ≥ ICC > 0.75), and excellent (≥
88 0.75) (Rosner, 2010). The lower the ICC for a certain compound is, the higher the probability that a single
89 spot measurement could lead to a misclassification of the internal exposure to this chemical.

90 Many recent studies have reported ICCs for several chemicals in different study designs and populations,
91 however, the wealth of these ICCs has not yet been used to evaluate variability over different chemical
92 classes and recommend appropriate study designs for a particular population and time window of exposure.
93 Compared to their older, more persistent counterparts, these chemicals are expected to present larger
94 variability and thus classic biomonitoring studies based on one spot sample might result in substantial over-
95 or underestimation of the average exposure of an individual. In this review, we summarize the ICCs obtained
96 in the available studies for specific emerging, non-persistent chemicals and demonstrate how the ICCs and
97 thus variability in concentrations of these chemicals were influenced by different factors, such as timing and
98 duration of sampling, dilution/correction factor of urine, and the characteristics of the study population. We
99 aimed to collect and highlight relevant available data on temporal variability expressed as ICCs for a broad
100 range of (emerging) organic contaminants to allow researchers to optimize study design and interpretation
101 of biomonitoring results for future studies.

102 103 **2. Methods**

104 The search for relevant papers was performed using PubMed and Web of Science by employing a
105 combination of relevant keywords. The search for each compound class of interest contained the following
106 key words: 'urine' with "variability OR variation OR ICC" and a specific key word related to the individual
107 chemicals in the searched class, including chemical abbreviations. The specific key words are summarized in
108 Table 1. No exclusion criteria for the year of publication were applied during the literature research.
109 However, studies that collected urine samples only during 24 h or one full day were excluded from this

110 review. The influence of urinary dilution on the variability was evaluated by including concentrations
111 corrected for creatinine levels (CRT), specific gravity (SG) or osmolality (OSM). Information related to the
112 following compound classes (and their metabolites) was investigated: bisphenols, pyrethroids, parabens,
113 phthalates, alternative plasticizers and organophosphate flame retardants. Several other classes, such as
114 neonicotinoids, organophosphate pesticides, polycyclic aromatic hydrocarbon metabolites or triclosan were
115 not included in this review due to data scarcity or knowledge about episodic exposures for some chemicals
116 (e.g. several classes of pesticides).

117

118 **3. Determinants of ICC values for various classes of chemicals**

119 **3.1. Bisphenols**

120 Bisphenols are high-production volume chemicals used to produce polymers employed in various
121 applications such as construction materials, adhesives, housing for electronic equipment, medical devices
122 and protective coatings (Geens et al., 2012). However, they can also be used in their monomeric form as an
123 additive in thermal paper products (Liao and Kannan, 2011; Vervliet et al., 2019). Additionally, due to
124 degradation or incomplete polymerization, residual free bisphenol can leach out of the aforementioned
125 applications and therefore be a source for human exposure (Kovačič et al., 2020). Historically, bisphenol-A
126 (BPA) was used extensively, but due to suspected endocrine disruptive properties, worldwide regulations on
127 its application are implemented (European Food Safety Authority, 2015; Kawamura et al., 2014). This leads
128 to the increasing replacement of BPA with less characterized alternatives, such as other bisphenols. Human
129 exposure and pharmacokinetics of BPA have been studied extensively for BPA, while fewer studies have
130 investigated alternative bisphenols. There is no consensus yet on this topic, but based on the currently
131 available data, it is accepted that exposure routes and behavior of alternative bisphenols are relatively similar
132 to BPA. The main exposure route to bisphenols is thought to be oral ingestion, and absorption is rapid and
133 almost complete. After ingestion, bisphenols are almost completely metabolized to the non-toxic
134 glucuronide metabolite and quickly excreted in urine (half-life < 7-8 h) (Khmiri et al., 2020; Oh et al., 2018;
135 Teeguarden et al., 2015; Thayer et al., 2015). Bisphenols have been detected in various biological matrices,
136 with urine being the matrix of choice to measure internal human exposure. As a consequence of its
137 replacement, internal BPA exposure has decreased in recent years, while extensive internal exposure to
138 alternative bisphenols has recently been reported for the first time in populations (Gys et al., 2020; Gys et
139 al., 2021a).

140

141 **Variability in bisphenol concentrations**

142 An overview of the 21 available studies that report short- and long-term variability and ICCs for
143 bisphenols is presented in Table S1. BPA has been the most investigated bisphenol in urine, as its temporal
144 variability has been evaluated in eight studies in the general population (Faÿs et al., 2020; Gys et al., 2021b;

145 Koch et al., 2014; Lassen et al., 2013; Morgan et al., 2018; Townsend et al., 2013; Wang et al., 2019b; Ye et
146 al., 2015), ten papers in pregnant women (Braun et al., 2011; Braun et al., 2012; Casas et al., 2018; Fisher et
147 al., 2015; Guidry et al., 2015; Jusko et al., 2014; Meeker et al., 2013a; Philippat et al., 2013; Vernet et al.,
148 2018; Yazdy et al., 2018), and four in children (Casas et al., 2018; Heffernan et al., 2014; Stacy et al., 2016;
149 Teitelbaum et al., 2008). For BPA, reported ICCs varied widely, from 0.04 to 0.60, depending on the sampling
150 time frame and frequency, the total number of collected samples and the applied urinary dilution correction
151 in the respective study (Gys et al., 2021b; Sakhi et al., 2018). The time frame in which samples were collected
152 differed greatly, ranging from two days to two years, obviously implying a limitation in comparing results
153 from these studies (Koch et al., 2014; Lassen et al., 2013; Morgan et al., 2018; Wang et al., 2019b). Four (Koch
154 et al., 2014; Lassen et al., 2013; Morgan et al., 2018; Wang et al., 2019b) out of eight studies in the general
155 population have shown ICCs of BPA estimated from 24 h-urine sampling in general adult population. Despite
156 differences in the collection method of these daily pooled samples, dilution adjusted (SG or CRT) ICCs
157 between these studies are quite consistent (ICCs 0.15 - 0.28) compared to those based on spot or morning
158 void (MV) urine.

159 In pregnant women, urinary BPA variability has been estimated from spot urine samples, MVs or daily
160 pools and resulted in ICCs ranging from 0.07 to 0.60. In all but one of these studies, ICCs estimated based on
161 dilution-adjusted spot urine were lower than non-adjusted spot urine (Braun et al., 2011; Braun et al., 2012;
162 Casas et al., 2018; Fisher et al., 2015; Guidry et al., 2015; Jusko et al., 2014; Meeker et al., 2013a; Philippat
163 et al., 2013; Vernet et al., 2018; Yazdy et al., 2018). Due to physiological changes occurring throughout
164 pregnancy, urinary dilution status may vary depending on the trimester in which samples were collected (Lee
165 et al., 2021). In children, two studies have evaluated the influence of urinary dilution correction on the
166 variability of urinary BPA concentrations. In both publications, it was reported that the ICC increased when a
167 correction with CRT was applied (Stacy et al., 2016; Teitelbaum et al., 2008). Despite the number of studies
168 that have assessed temporal variability of urinary BPA, so far no consensus had been established on the most
169 suitable study design for urine sampling in order to achieve a reliable exposure assessment of BPA. However,
170 this literature overview finds that a high variability could in general be observed for urinary BPA
171 concentrations, regardless of study design, population or dilution correction.

172 For alternative bisphenols, data on temporal variability of repeated measurements is scarce, with very
173 few publications available per compound for the BPA analogues, BPAP, BPF and BPS (Gys et al., 2021b; Vernet
174 et al., 2018; Wang et al., 2019b). Variability of urinary BPAP concentrations has been studied just once and
175 proved to be high for spot samples (ICC 0.09) when not corrected for urinary dilution (Gys et al., 2021b). For
176 BPF, ICCs ranged from <0.01 (over the course of 12 weeks) to 0.44 (over 5 days) in different adult study
177 populations (Faÿs et al., 2020; Gys et al., 2021b; Wang et al., 2019b). From these three studies, no conclusion
178 could be drawn on the influence of the sample type (spot versus MV) on the reproducibility of urinary BPF
179 concentration. The variability of BPS concentrations in urine was assessed in three studies as well, showing

180 differing but low reproducibility, with ICCs varying from <0.01 (over 5 days) to 0.20 (over 19 weeks) (Faÿs et
181 al., 2020; Gys et al., 2021b; Vernet et al., 2018).

182 Despite the differences in study design and time frame, the outcomes of this small number of studies
183 indicate that temporal variability is high for alternative bisphenols and collecting only one sample per
184 participant could result in a misclassification of exposure. In addition, there is no consistent relation between
185 the sampling timeframe (ranging from 5 days up to 26 weeks) and the ICC for these compounds. These
186 differences between studies might partially be explained by the differing extent of application of these
187 emerging compounds between regions, and thus strongly varying exposure patterns. Furthermore, the
188 reported results of the abovementioned studies depend greatly on the included compounds and their
189 respective limits of quantification, in particular for the alternative bisphenols. Correcting for the dilution of
190 urine samples using the CRT or SG yields slightly higher ICCs (Gys et al., 2021b; Vernet et al., 2018). However,
191 this comparison between urinary dilution adjustments has been carried out only in two studies and more
192 data is needed to confirm the differences in the adjustment procedures.

193

194 **3.2. Synthetic pyrethroids**

195 Synthetic pyrethroids (SPs) are a group of insecticides commonly used around the world. They are more
196 stable when exposed to sunlight than their natural precursors - pyrethrins (Bradberry et al., 2005; Kaneko,
197 2010; WHO, 2005). Due to their high insecticidal activity, low acute toxicity to mammals, and low persistence
198 in the environment, SPs are widely used for crop protection, as well as in medical and animal care products.
199 Furthermore, SPs are recommended by the WHO for the treatment of mosquito bednets in tropical countries
200 for malaria vector control (WHO, 2021). Although SPs are found to be relatively safe for humans (e.g.,
201 compared to organophosphate insecticides), a higher urinary concentration of SP metabolites has been
202 recently linked to neurodevelopmental and behavioral problems in children (Oulhote and Bouchard, 2013;
203 Viel et al., 2015) and to abnormal reproductive parameters in adults (Jurewicz et al., 2020a; Jurewicz et al.,
204 2015; Jurewicz et al., 2020b; Meeker et al., 2008; Meeker et al., 2009; Radwan et al., 2015). Recently, the
205 concern about the safety of SPs has been emphasized by including pyrethroids on the list of prioritized
206 substances provided by HBM4EU Initiative (Hbm4Eu, 2018). Dietary intake is considered a significant route
207 of exposure to pyrethroids. However, non-dietary factors, such as dust ingestion, inhalation of indoor air and
208 dermal exposure due to the use of insecticides on household pets, seem to play an additional and important
209 role in exposure of humans to SPs (Morgan et al., 2007; Rodzaj et al., 2021; Yoshida et al., 2021). After
210 entering the human body, pyrethroids are rapidly absorbed, metabolized, and eliminated in the urine as
211 phase-II conjugates or in free form (Kaneko, 2010; Ratelle et al., 2015a; Ratelle et al., 2015b; Sams and Jones,
212 2012).

213 The most frequently quantified pyrethroid metabolites in human biomonitoring studies are non-specific
214 metabolites, such as 3-phenoxybenzoic acid (3PBA) and cis/trans-3-(2,2-dichlorovinyl)-2,2-dimethyl-(1-

215 cyclopropane) carboxylic acid (cis/trans-DCCA) (Barr et al., 2010; Garí et al., 2018; Oulhote and Bouchard,
216 2013; Viel et al., 2015; Wielgomas et al., 2013; Ye et al., 2016). As these are common metabolites of several
217 SPs, they are widely employed in the assessment of aggregated exposure to SPs. Since the pyrethroid
218 metabolites are primarily excreted by kidneys, urine has become the primary biological matrix used in human
219 biomonitoring studies. However, short urinary elimination half-lives of SP metabolites (< 7 h) (Ratelle et al.,
220 2015a; Ratelle et al., 2015b; Sams and Jones, 2012) make the exposure assessment challenging.

221

222 **Temporal variability in synthetic pyrethroids concentration**

223 The literature search on the temporal variability in the urinary excretion of SP metabolites resulted in 9
224 papers describing short- and long-term variability of 3PBA urinary concentration in general populations (Faÿs
225 et al., 2020; Klimowska et al., 2020; Li et al., 2019a; Lin et al., 2021; Morgan et al., 2016; Wielgomas et al.,
226 2013), pregnant women (Barkoski et al., 2018) and children (Attfield et al., 2014; van Wendel de Joode et al.,
227 2016). Nevertheless, only 3 papers reporting long-term studies included other metabolites, such as cis- and
228 trans-DCCA (Attfield et al., 2014; Klimowska et al., 2020; Li et al., 2019a). Although different sampling
229 strategies were employed in each study, the results are consistent for most SP metabolites.

230 In general, a high variability was observed for urinary concentrations of 3PBA with ICCs ranging from
231 0.00 to 0.35 (Attfield et al., 2014; Barkoski et al., 2018; Faÿs et al., 2020; Li et al., 2019a; Lin et al., 2021;
232 Morgan et al., 2016; van Wendel de Joode et al., 2016). The reproducibility was only slightly improved when
233 SG- and CRT-adjustment was applied. Similarly, the type of sample (spot, MV, or 24 h) increased only slightly
234 the ICCs. On the contrary, however, two studies presented higher reproducibility for SP metabolites with
235 ICCs ranging from 0.35 to 0.91 (Klimowska et al., 2020; Wielgomas et al., 2013). The overview of available
236 studies reporting ICCs for SP metabolites is presented in Table S2.

237 A recent study on longitudinal temporal variability showed consistently high ICCs for three target SP
238 metabolites (ICCs: 0.75-0.91) (Klimowska et al., 2020). The study relied on the monthly collection of one or
239 two complete 24 h urine samples over 12 consecutive months. The benefit of this sampling design is that
240 biomarker concentration in a 24 h sample represents an average daily exposure level, and thus is less
241 susceptible to the intra-day fluctuations in chemical urinary excretion (Aylward et al., 2014). Interestingly, a
242 similar low variability (high ICC) was observed for 3PBA in a short-term study when all urine spot samples
243 were collected by seven adult volunteers over seven consecutive days (Wielgomas et al., 2013). In that study,
244 the concentration of 3PBA was examined in each urine void, MV, and 24 h urine sample prepared by pooling
245 all voids provided on a given day. Similar ICCs were obtained for spot and simulated 24 h samples (ICC: 0.60
246 and 0.68, respectively), whereas lower reproducibility was observed for MVs (ICC: 0.35). However, the
247 highest ICCs occurred in spot (ICC: 0.85) and 24 h samples (ICC: 0.80) after adjustment to CRT level. Based on
248 these results, Wielgomas (2013) concluded that a single random urine sample adequately represents the
249 average exposure level to 3PBA precursors over a 7-day period.

250 In contrast to these findings, when only four random spot samples were collected over a week, the
251 variability was rather high (ICCs: 0.01-0.05) (Lin et al., 2021). Likewise in another study, collection of two MVs,
252 bedtime voids or 24 h samples over a week did not improve the reproducibility (ICCs: 0.00-0.21) (Morgan et
253 al., 2016). The discrepancies among the various short-term studies may be due to differences in sampling
254 strategy and the number of participants, since only seven individuals contributed to the former one, whereas
255 43 and 50 individuals participated in the latter two studies, respectively. On the other hand, Pleil and Sobus
256 (2013) defined the number of measurements per person as a reliable indicator for ICC quality (Pleil and
257 Sobus, 2013). In the study provided by Wielgomas (Wielgomas et al., 2013) participants collected averagely
258 5.7 samples daily giving about 40 spots over seven days. Only two long-term studies included similar number
259 of individual spot samples, up to 40 samples per person over 44 days (Li et al., 2019a) or 43 samples per
260 person over six months (Faÿs et al., 2020). However, it is expected that exposure level, from both diet and
261 indoor environment, over short period is much less diversified than over several weeks or months.
262 Interestingly, slightly higher ICCs in the range of 0.29-0.35 were computed from results in morning and
263 bedtime voids collected by children at least three months apart (Attfield et al., 2014; van Wendel de Joode
264 et al., 2016).

265 Since low ICCs were calculated for most studies, a few authors attempted to calculate number of
266 samples required to achieve a satisfactory estimate of the individual's average 3PBA concentration over a
267 defined period of time (Faÿs et al., 2021; Li et al., 2019a; Lin et al., 2021; Morgan et al., 2016). The number
268 of samples that would be required for reliable participant's classification ranged from 14 (Lin et al., 2021) to
269 800 (Morgan et al., 2016) for spot samples collected over a week and bedtime voids over 6 weeks,
270 respectively.

271

272 **3.3. Parabens**

273 Parabens, a group of esters of *p*-hydroxybenzoic acid with a broad spectrum of activity against
274 microorganisms, are commonly applied as preservatives in foods, personal care products (PCPs) and
275 cosmetics, and pharmaceutical products. Their widespread use is also attributed to several beneficial
276 features, such as relative safety of use, chemical stability, sufficient solubility in water, and no perceptible
277 odor or taste (Błędzka et al., 2014). Nevertheless, antimicrobial activity, as well as the toxicity of parabens,
278 are directly proportional to the chain length of the ester group, thus more than one ester is usually used in a
279 single product. The combination of methyl (MeP) and propyl (PrP) ester is utilized most frequently (Błędzka
280 et al., 2014; Guo et al., 2013). The main concern about parabens relates to their weak estrogenic activity and
281 potential to disturb the human endocrine system; however, the available data considering this issue remains
282 inconclusive (ScCs, 2011; ScCs, 2021).

283 Following oral administration, parabens are rapidly absorbed from the gastrointestinal tract and then
284 metabolized by non-specific esterases to *p*-hydroxybenzoic acid (Błędzka et al., 2014; Soni et al., 2005). Only

285 a relatively small fraction of the absorbed dose (< 20%, depending on paraben) is excreted in urine as a parent
286 compound in free form or as conjugates with glucuronic acid and sulfate (half-life < 7 h) (Moos et al., 2016;
287 Shin et al., 2019). Parabens are also partially absorbed through the skin, which is important since the use of
288 PCPs is regarded as the greatest contributor to the paraben burden, whereas diet is mentioned as the second
289 exposure source for humans (Canada, 2019; Huang et al., 2021; Moos et al., 2015; Pollack et al., 2018; Smarr
290 et al., 2017).

291

292 **Variability in paraben concentrations**

293 In total, 17 studies describing temporal variability in urinary excretion of parabens in general population
294 (Dewalque et al., 2015; Engel et al., 2014; Huang et al., 2021; Kim et al., 2020b; Koch et al., 2014; Nishihama
295 et al., 2018; Pollack et al., 2016; Sakhi et al., 2018; Smith et al., 2012; van der Meer et al., 2021), pregnant
296 women (Casas et al., 2018; Guidry et al., 2015; Li et al., 2019b; Meeker et al., 2013a; Philippat et al., 2013;
297 Vernet et al., 2018; Yazdy et al., 2018) and children (Casas et al., 2018; Kim et al., 2020b) were retrieved from
298 the literature search. ICCs for two parabens (MeP and PrP) were reported in all studies. Butylparaben (BuP)
299 was excluded from variability assessment in six studies due to the low detection frequency (<60%), whereas
300 EtP was not included in five study protocols. An overview of available studies reporting ICCs for parabens is
301 presented in Table S3. Overall, ICCs ranged from 0.02 to 0.92 across all studies indicating very poor to
302 excellent reproducibility. Correction of urinary paraben concentrations by either SG- or CRT-normalization
303 only slightly improved ICCs. An increase in ICCs was obtained when FMVs or 24 h urine samples were used
304 instead of spot samples. Nevertheless, ICCs obtained within a single study were rather similar for all
305 parabens.

306 High variability (or low ICCs) was observed for all studies in which a small number of samples was
307 collected over a longer period of time. Low ICCs were obtained for two random spots (ICCs < 0.30) (Engel et
308 al., 2014) and two 24 h urine samples (ICCs < 0.42) (van der Meer et al., 2021) collected from adults at least
309 two years apart. Higher ICCs were reported in other longitudinal studies in which repeated spot samples
310 were provided by non-pregnant women and male adults over less than five months (ICCs 0.28-0.68)
311 (Dewalque et al., 2015; Nishihama et al., 2018; Pollack et al., 2016). However, lower variability for MeP and
312 EtP was observed in men (ICCs 0.56-0.58) than women (ICCs 0.40-0.43) (Dewalque et al., 2015; Nishihama et
313 al., 2018; Pollack et al., 2016) which may be due to a different pattern of PCPs use.

314 Two intervention studies on short-term variability in paraben urinary concentrations have been recently
315 published (Huang et al., 2021; Koch et al., 2014). In both studies, urine collection was carried out during two
316 periods of high and one period of low exposure level (intervention period) when participants used typical
317 cosmetics and PCPs with or without parabens, respectively. Huang et al. (2021) assessed the variability
318 separately for each of the three 6-day periods and found that the ICCs generally were in close agreement
319 between all periods, even though paraben concentrations were at least 3-fold lower in samples collected

320 during the intervention period (Huang et al., 2021). The lowest variability in ICCs was obtained for spot
321 samples after CRT-adjustment of concentrations by a toxicokinetic model (TK-model) (Huang et al., 2021).
322 Koch et al. (2014) observed an increase in ICCs in the 24 h urine (ICCs 0.72-0.92) comparing to spot urine
323 samples (ICCs 0.39-0.82). However, in this study a large within-individual variability of the paraben exposure
324 levels was observed, which combined with a large variation between individuals, may explain relatively high
325 ICCs (Koch et al., 2014).

326 A few studies in pregnant women have been conducted under three slightly different settings.
327 Regardless of the study design, poor to moderate reproducibility was observed (ICCs 0.24-0.64). The simplest
328 study design relied on collection of one random spot sample provided at three times during gestation and
329 resulted in ICCs in the range of 0.31-0.64 (Li et al., 2019a; Meeker et al., 2013a; Philippat et al., 2013).
330 Furthermore, no increase in ICCs was observed when one weekly pool consisting of seven daily pools were
331 provided in each trimester (ICCs 0.36-0.54) (Casas et al., 2018) or repeated spot samples every 3-4 gestational
332 weeks (ICCs 0.24-0.62) (Guidry et al., 2015; Yazdy et al., 2018). Moreover, there was no difference in
333 variability throughout pregnancy when assessment was based on three random spot samples (ICCs 0.40-
334 0.85) or three weekly pools (ICCs: 0.33-0.86) (Vernet et al., 2018).

335 Although the variability of paraben concentrations in adults has been extensively studied, data on ICCs
336 in children are still scarce. The short-term analysis of daily pools collected from 6-11 year old children during
337 four consecutive days showed a good reproducibility (ICCs 0.58-0.68) which decreased in long-term analysis
338 when two weekly pools were provided six months apart (ICC < 0.31) (Casas et al., 2018). Due to the
339 differences in the metabolism and use of PCPs, which are considered to be the main source of exposure to
340 parabens, data on variability in adults should not be extrapolated to children.

341

342 **3.4. Phthalates**

343 Phthalates are the principal plasticizers for polyvinyl chloride (PVC) and are used for a wide range of
344 materials at low cost. While high molecular weight phthalates, such as dibutyl phthalate (DBP), butylbenzyl
345 phthalate (BBzP), di-2-ethylhexyl phthalate (DEHP), and di-isononyl phthalate (DiNP), were used for food
346 contact materials and other plastic products, the low molecular weight phthalates, such as dimethyl
347 phthalate (DMP) and diethyl phthalate (DEP), were added in PCPs as fragrances and additives (Malveda et
348 al., 2018). The main source of exposure to phthalates was thought to be diet due to migration from plastic
349 food packaging or containers (Wormuth et al., 2006). However, due to the increasing use of plastics for many
350 other applications and because of the leaching of phthalates into indoor and outdoor environments,
351 ingestion of dust, inhalation, and dermal absorption from PCPs are also important exposure routes. Adverse
352 health effects of phthalates on the endocrine system (eg. diabetes, obesity, thyroid hormone), asthma and
353 allergies, reproductive system (eg. precocious puberty, decreased anogenital distance, decreased sperm

354 quality) and neurodevelopment (eg. ADHD) have been reported from both experimental and epidemiological
355 studies (Chang et al., 2021).

356 The concentrations of phthalate metabolites from single spot urine are generally used to evaluate
357 exposure levels to phthalates. However, the elimination of phthalate diesters in urine is relatively fast and
358 their half-lives are short. Elimination of DnBP, DiBP, DEHP, and DiNP in urine after a single dose occurs within
359 24 h (DnBP and DiBP), 2-4 h (DEHP), and 48 h (DiNP) (Koch and Angerer, 2007; Koch et al., 2004; Koch et al.,
360 2012) have been reported in healthy human volunteers. In addition, the half-lives of the first elimination
361 phase of DnBP, DiBP, and DEHP metabolites are approximately 2.6 h, 3.9 h, and 2 h, respectively. In the
362 terminal phase of elimination, the half-lives of DEHP and DiNP metabolites are approximately 5 h and 12-18
363 h, respectively. However, because humans are continuously exposed to phthalates via various sources,
364 phthalates are categorized as “pseudo-persistent” chemicals.

365

366 **Variability in phthalate concentrations**

367 Twenty-three papers discussing the temporal variability in phthalate metabolites were retrieved from
368 the literature search. The description of these studies and the ICCs for phthalate metabolites can be found
369 in Table 2. Metabolites of low molecular weight phthalates, such as MEP, MnBP, MiBP, and MBzP have a
370 good ICC (ICC > 0.4), while those of the high molecular weight phthalates, such as DEHP metabolites have a
371 poor ICC (ICC < 0.4). This difference can be attributed to the difference in applications. As MEP, MnBP, and
372 MiBP are contained in PCPs, they are used daily and have little variation in the usage patterns, resulting in
373 more constant internal exposure levels. For the higher molecular weight phthalate metabolites, such as
374 metabolites of DEHP, their main exposure source is represented by food and food contact materials, which
375 are prone to have a more varied usage. Moreover, gender does not have a significant impact on the ICCs of
376 phthalates (Dewalque et al., 2015; Fromme et al., 2007).

377 In a comprehensive study of the short term variability of concentrations in adults (Bastiaensen et al.,
378 2020a), dilution was adjusted using two different methods: uncorrected, and correcting for SG and CRT on
379 the same adult urine samples. The correction had a large effect on the highest ICCs for the CRT-correction,
380 which is in line with the ICCs of two other studies in the adult population (Table 2). Apart from dilution, both
381 MV and spot urine samples were collected, showing higher ICCs for MV samples. Additionally, Frederiksen et
382 al. also included 24h-sampling, for which similar ICCs were found compared to MV, with higher ICCs for DEP,
383 DBP and BBzP. Across studies, there is no difference between different sampling methods, likely due to the
384 high variability. Based on the current data, it is advisable to use MV samples. As the collection of 24 hour
385 urine is more complex and the small increase of low molecular mass phthalates might not warrant the added
386 complexity.

387 When dilution adjustment was investigated in urine of pregnant women collected across pregnancy, SG-
388 correction resulted in similar ICCs as uncorrected urine, while CRT-correction resulted in lower ICCs (Table 2).

389 Although there is no comparative study, studies of periods longer than 12 weeks (or one pregnancy trimester)
390 have lower ICCs than studies with ICCs of shorter timeframes, indicating that single measurements are not a
391 good predictor for exposure during whole pregnancy. Most of the studies that examined ICCs from spot urine
392 samples throughout pregnancy at multiple time points until delivery have concluded that more than one
393 measurement at different times of day is required to get an accurate exposure assessment, particularly when
394 diet is the main source of exposure to the chemicals of interest (Adibi et al., 2008; Cantonwine et al., 2014;
395 Fisher et al., 2015; Valvi et al., 2015). On the other hand, it is also necessary to consider which exposure
396 windows of pregnancy are most appropriate to use for the factor being examined when a study design that
397 prospectively examines the association with maternal exposure concentrations showed low reproducibility.

398 While many studies have been performed for adults and some on pregnant women, temporal variability
399 studies for phthalate metabolites on children are scarce, with only 3 reported studies. These studies were
400 carried out in the US (Teitelbaum et al., 2008; Watkins et al., 2014) and the EU (Casas et al., 2018). Watkins
401 et al. studied both short term (average two weeks) and long term (1-5 years) variability for MEP, cx-MEPP
402 and MBzP and reported poor ICCs for all three compounds among 1-5 years old children (Watkins et al., 2014).
403 ICCs of MEP and MBzP were lower in children than in adults. Creatinine correction on the children's samples
404 did not improve the ICCs. Moreover, no improvement was seen when comparing the short term variability
405 of 2 weeks with the long-term variability of one year. This suggests that especially for younger children like
406 during infancy, toddlers, and preschool age, a single spot urine sample may be a reasonable measure of short-
407 term (daily) exposure to phthalates that are linked to routine behaviour (e.g., frequently use of certain
408 products). However, such sampling design may not adequately capture exposure over weeks or months,
409 since diet, PCPs use, and routine behaviour change dramatically over the first years of life. These findings are
410 confirmed by Casas et al., which presented higher reliability of short-term (between-day) than long-term (>
411 6 months) for metabolites of DEP, DnBP, DiBP, and BBzP, which are present in PCPs (Casas et al., 2018).

412

413 **3.5. Alternative plasticizers**

414 Due to endocrine disrupting potential and adverse effects in particular on children, the use of several
415 phthalates, such as DEHP, DBP, BBzP, has been restricted in plastic toys and childcare articles, as well as in
416 food contact materials by international legislation (ECHA, 2012; 2018). Terephthalates (e.g. di-2-ethylhexyl
417 terephthalate-DEHTP), adipates (e.g. di-2-ethyl-hexyl adipate-DEHA), bis-(2-propylheptyl) phthalate
418 (DPrHpP), and di-(iso-nonyl)-cyclohexane-1,2-dicarboxylate (DINCH), are used as alternative plasticizers for
419 the traditional phthalates. The most used adipate is DEHA, which is used as a plasticizer for PVC, surface
420 coatings, and rubber (BASF Technical information).

421 Half-lives of DPrHpP, DEHTP, DINCH, and DEHA have been reported as 6-8 h (DPrHpP), 7 h (DEHTP), 10-
422 18 h (DINCH), and 2.1-2.8 h, respectively (Koch et al., 2013; Leng et al., 2014; Lessmann et al., 2018; Nehring
423 et al., 2020). Human biomonitoring studies have reported that positive temporal trends have been

424 determined for the DINCH metabolites in the Swedish and the Danish general population (Frederiksen et al.,
425 2020; Gyllenhammar et al., 2017), suggesting a worldwide increase of DINCH exposure over time. In general,
426 these alternative plasticizers are considered safer alternatives to DEHP and other traditional phthalates.
427 However, recent epidemiological studies have reported adverse effects of alternative plasticizers in early life;
428 e.g., increased serum total T3 in Swedish pregnant women (Derakhshan et al., 2021), increased risk of
429 preterm birth (Zhang et al., 2020), lower total testosterone among general U.S men age ≥ 40 y (Woodward et
430 al., 2020) and higher free testosterone among general US women age >20 y (Long et al., 2021).

431

432 **Variability in alternative phthalate and plasticizer concentrations**

433 As opposed to the traditional phthalates, fewer studies on the ICCs of alternative phthalates and
434 plasticizers were performed. Therefore, only ten studies could be collected, as shown in Table S4 and S5.
435 Only two studies have calculated ICCs in children, although they are a more sensitive group, as well as have
436 different metabolization and elimination capabilities compared to adults (Watkins et al., 2014). Moreover,
437 most studies have only focused on metabolites of two alternative phthalates, DINCH and DINP, with
438 metabolites of DINP being the most studied compounds. Only one AP metabolite, mono(2-ethyl-5-
439 hydroxyhexyl) terephthalate (OH-METHP), had fair to good reproducibility (ICC > 0.4), and all other measured
440 AP metabolites had poor reproducibility (ICC < 0.4) with among them the DINP, DIDP and DINCH metabolites.
441 DEHTP, the parent compound of OH-METHP, has similar applications to DEHP (phthalates), but has higher
442 reproducibility, probably due to specific toxicokinetic properties.

443 The metabolites of APs that were most studied are all secondary metabolites. However, Fajis et al.
444 (2020) also studied the primary metabolites of DINP and DINCH (Faÿs et al., 2020). They found that MINP
445 (ICC: 0.27) has a slightly higher ICC than Cx-MINP (ICC: 0.21) and OH-MINP (ICC: 0.09) (Table S4). For DINCH,
446 they found smaller differences with MINCH (ICC: 0.11) and oxo-MINCH (ICC: 0.10) which were lower
447 compared with OH-MINCH (ICC: 0.14) and cx-MINCH (ICC: 0.19) (Table S5). In the only comparative ICC study
448 on the general population (Bastiaensen et al., 2020a), the dilution adjustment by either CRT or SG increased
449 the ICCs when compared with unadjusted ICCs. Additionally, MV samples had slightly higher ICCs compared
450 to spot samples.

451 Comparative studies on the ICCs in pregnant women and children are scarce. Only three studies are
452 comparative, comparing no dilution adjustment with either SG or CRT. From these studies, it seems that ICCs
453 are unaffected by urinary SG- or CRT-correction. However, short term variability in children increased for
454 CRT-correction (Table S5). Additional comparisons and recommendations could not be drawn for the
455 alternative plasticizers due to the limited data collected. Comparative ICC studies applying different
456 biomonitoring parameters or focusing on specific risk groups are needed to allow for further clarification.

457

458 **3.6. Phosphate flame retardants and plasticizers**

459 Phosphate flame retardants and plasticizers (PFRs) are a class of chemicals widely used in commercial
460 products, such as textiles, plastics, electronic devices, food contact materials, paints and furniture. PFRs were
461 introduced as alternatives to brominated flame retardants, although toxicological studies have
462 demonstrated potential adverse effects, such as endocrine disruption of these replacement chemicals. The
463 release of PFRs from consumer products has resulted in the contamination of the indoor and outdoor
464 environment, which could lead to significant exposure to humans as a result of dust or food ingestion,
465 inhalation or dermal absorption. Indoor dust is an important exposure source for PFRs, in particular for
466 children who spend more time indoors, have more frequent hand-to-mouth activities and have lower body
467 weights compared to adults (Araki et al., 2014; Heffernan et al., 2014; Hoffman et al., 2014). According to
468 recent studies, dietary intake is of equal or greater importance for human exposure to PFRs due to higher
469 average food consumption (Kim et al., 2020a; Poma et al., 2017; Poma et al., 2018; Xu et al., 2015). Another
470 exposure route to PFRs is the inhalation of contaminated air, with the main contributors being PFRs with
471 higher vapor pressures (Wong et al., 2018; Xu et al., 2016; Zhou et al., 2017). These results indicate that
472 exposure routes can be divergent relative to the various physicochemical properties of individual PFRs.

473 PFRs are well absorbed and distributed after oral dosage. PFRs have a weak association with lipid-rich
474 tissues which suggest they are metabolized and rather excreted than accumulated in the body (Hou et al.,
475 2016). Studies on the toxicokinetics of PFRs are limited, but they are consistent with short half-lives ranging
476 from 0.7 to 24h (Bui et al., 2017; Hou et al., 2016; van der Veen and de Boer, 2012). Although PFRs were also
477 be reported in whole blood, serum and plasma (Hou et al., 2020; Wang et al., 2020), the preferred matrix for
478 human biomonitoring is urine, because of the rapid metabolism and excretion of PFRs (Hou et al., 2016).
479 Regarding the temporal variability of PFR biomarkers in urine, the fast metabolism and excretion suggest
480 that a single urinary measurement would capture only recent exposure (of previous few days), while poor
481 reproducibility between measurements points to episodic exposure.

482

483 **Variability in PFR concentrations**

484 Several studies investigating ICCs of PFRs in general population (adults, pregnant women and children)
485 are summarized in Table S6. Only PFR biomarkers with reports in more than two studies were listed there.
486 Several biomarkers, such as 5-HO-EHDPHP, DoCP+DpCP, BCIPP, or EHPPH, with reported ICCs in only one
487 study, are not included in the overview Table S6 and in the discussion.

488 For pregnant women, the ICC range for PFR biomarkers indicate low reproducibility in the late pregnancy
489 (Percy et al., 2020), with CRT-normalized ICCs slightly lower than the unadjusted ICCs (Table S6). This suggests
490 that a single measurement during pregnancy cannot accurately predict the exposure to PFRs throughout the
491 whole pregnancy. Additionally, pregnant women experience plasma volume expansion and altered renal
492 function (Cheung and Lafayette, 2013), which can lead to increased variation in the concentrations of PFR
493 biomarkers. Romano et al. and Hoffman et al. (2017) found good reproducibility for urinary PFR metabolites

494 possibly due to more stable exposure sources, sampling years, higher population homogeneity and even
495 study design and population size (Hoffman et al., 2017; Romano et al., 2017).

496 Meeker et al. (2013) reported moderate to strong reproducibility between measurements of DPHP and
497 BDCIPP in adult men who did not experience significant physiological changes between sampling times
498 (Meeker et al., 2013b). The ICCs of PFR metabolites in males were > 0.35 , whereas in females they were
499 between 0.05 and 0.19 (Wang et al., 2019a), indicating that a higher variability of PFR metabolites in females
500 than in males, probably due to sex-specific physiology and lifestyle factors (e.g., physical activity and PCP
501 use).

502 Because MV samples are more concentrated, some PFR metabolites had higher reproducibility in MVs
503 than spot samples (Hoffman et al., 2014; Meeker et al., 2013b; Wang et al., 2019a). Measurements of BDCIPP
504 showed good reproducibility in MVs (ICC range 0.44–0.88), but fair reproducibility in spot samples (ICC range
505 0.35–0.62). Demographic characteristics (e.g., gender and BMI) of the study population can also be
506 responsible for the variation (Wang et al., 2019a). Wang et al (2021) also noticed a higher reproducibility in
507 some PFR metabolites among individuals with a higher BMI, probably due to differences in dietary
508 consumption, physical exercise, and metabolism kinetics (Wang et al., 2021).

509 The urinary concentrations of PFR metabolites in Asians showed higher variability (lower ICCs: 0.20–
510 0.26) than in Caucasians (higher ICCs: 0.32–0.67). There was no significant difference in variability of PFR
511 metabolite concentrations between the age groups of 30–40 y (ICC: 0.34–0.87) and >40 y (ICC: 0.17–0.70)
512 (Wang et al., 2019a). Individuals with BMI > 25 kg/m² showed a low ICC for BBOEP (ICC: 0.04), which
513 suggested that overweight or obese individuals may show higher variability in the urinary concentrations of
514 some PFR metabolites.

515 The inter-day variability for DPHP (ICC: 0.54, 95% CI: 0.37–0.74) was similar to those reported in urine
516 from pregnant women (ICC: 0.6, 95% CI: 0.4–0.7) (Hoffman et al., 2014), healthy adults (ICC: 0.51, 95% CI:
517 0.43–0.63) (Hoffman et al., 2015) and women (ICC: 0.42, 95% CI: 0.36–0.50) (Romano et al., 2017). Overall,
518 urinary PFR metabolite concentrations exhibited a moderate temporal reproducibility and CRT-adjustment
519 slightly improved the reproducibility.

520 Fair to good reproducibility was found for BCIPHIPP (SG-corrected ICC: 0.60), and BDCIPP (0.59) when
521 spot samples of five consecutive days were considered. Lower ICCs were observed for DPHP (0.30), EHPHP
522 (0.23) and 5-HO-EHDPHP (0.40) which suggest that concentrations of these compounds varied more during
523 the study period (Bastiaensen et al., 2020a). When only MV samples were considered, the reproducibility
524 improved for BDCIPP, BCIPHIPP and 5-HO-EHDPHP (SG-corrected ICCs of respectively 0.66, 0.69 and 0.60),
525 whereas the ICCs of DPHP (0.15) and BBOEHEP (0.36) decreased.

526 For the most frequently measured PFR metabolites, the urinary BDCIPP showed moderate-to-strong
527 temporal reproducibility, whereas ICCs for DPHP were lower, indicating a larger variation over time (Table
528 S6). The reproducibility of measurements of PFR metabolites is not only influenced by exposure to

529 corresponding parent compounds, but may also be affected by their kinetics of absorption, distribution,
530 metabolism and elimination (Aylward et al., 2014). The suggested longer half-lives of chlorinated PFRs in
531 humans compared to aryl- and alkyl-PFRs (Wang et al., 2020) agree with the better reproducibility over time
532 for BCIPHIPP and BDCIPP compared to other metabolites (Bastiaensen et al., 2020a).

533 The relatively high variability in the DPHP concentrations (ICCs < 0.40 for most studies) is probably
534 attributable to the fact that DPHP is a metabolite of several parent PFRs (e.g., TPHP, EHDPHP, bisphenol A
535 bis (diphenyl phosphate) and resorcinol bis(diphenyl phosphate)). The largest contribution to the total
536 variance of urinary DPHP concentrations was the within-day variance in most studies. A higher diurnal
537 variation of DPHP is possibly due to inconsistent exposure to multiple sources. TPHP and EHDPHP were found
538 to be the main contributors to dietary exposure in foodstuffs which is more heterogeneous from day-to-day.
539 Similar findings have been reported for di(2-ethylhexyl) phthalate (DEHP) and bisphenol A (BPA) for which
540 diet is likely the main source of exposure; the short-term variation within an individual is generally greater
541 than the variation between individuals (resulting in low ICCs). PFR metabolites with more continuous and
542 stable sources had fair-to-good reproducibility (ICCs > 0.40).

543 Bastiaensen et al (2021) was the only study to sample healthy adults who provided all spot urine samples
544 during five consecutive days, to allow the study of diurnal variations and calculate short-term ICCs of PFRs
545 metabolites (Bastiaensen et al., 2020a). However, since age is a predictor of PFR exposure (Van den Eede et
546 al., 2015), the generalizability of ICCs from adults to children or adolescents is limited due to differences in
547 exposure patterns (related to lifestyle) and potential differences in metabolism (Aylward et al., 2014).

548

549 **4. Discussion**

550 This is the first review demonstrating the influence of specific factors, such as study populations (adults,
551 pregnant women, and children), sampling strategies (spot, MV, and 24 h), and type of urinary dilution
552 adjustments (non-adjustment, CRT-adjustment, and SG-adjustment) on the ICCs of wide range of short half-
553 life chemicals: bisphenols, pyrethroids, parabens, phthalates, alternative plasticizers, and PFRs.

554

555 **Reflection on ICC values**

556 All studies included in this review used ICC values as a frequently used statistical and non-dimensional
557 parameter to evaluate the reproducibility of repeated measurements for a selection of non-persistent
558 chemicals (Figure 1). Observed differences in the ICCs between studies may result from several reasons: 1)
559 the experimental design (how often and for what period of time samples are collected from the same study
560 participants), 2) sampling (MV, spot or 24 hours), 3) the pattern of exposure in a given geographical area or
561 country/population, 4) the ratio of the number of samples taken from the same participants to the number
562 of participants and/or 5) combinations of these components. In turn, these differences in ICCs may result
563 from the method of calculating the ICC, although (Pleil et al., 2018) showed that different methods of

564 calculating the variance components had little effect on the ICCs. These authors concluded that the precision
565 of ICC estimates is mostly affected by the distribution of the samples, the number of repeated
566 measurements, and the total number of samples. However, even for similar study designs, ICCs may vary
567 between the studies with the following possibly contributing to these findings: 1) different limits of
568 quantification (LOQs) in the applied analytical methods, which influence the detection frequency and the
569 distribution of the measurements. 2) various strategies for imputation of concentrations < LOQ, which in turn
570 might contribute to the ICC variability in particular for chemicals with a low detection frequency in the
571 studied population, depending on the cut-off applied for calculating the ICC in the respective study.

572

573 **Variation across chemical classes and study populations**

574 Figure 2 and Table S7 show the variation in ICCs for all short half-life chemicals or their metabolites
575 included in this review, divided per type of sampled population. Expectedly, the largest number of
576 publications on variability of urinary concentrations were available for the legacy chemicals, such as BPA and
577 MEP. The ICCs of particular chemicals, such as parabens (MeP, EtP, and PrP), low molecular weight phthalate
578 metabolites (MEP, MnBP, and MBzP) and BDCIPP tended to be relatively higher in the adult population than
579 in pregnant women (Table S7). In addition, median ICCs of MEP in adult population were significantly higher
580 than in children. Yet, they also presented a broader range of ICC values possibly an influence of the specific
581 study designs. On the other hand, BPA and 3-PBA showed the lowest ICCs in both adults and pregnant women.
582 Median ICCs of MEHP, oxo-MEHP, and DEHP showed also low ICCs (< 0.4) in both adults and pregnant women.
583 Chemicals related to the diet as a main exposure source, e.g. BPA, 3-BPA, and metabolites of DEHP, have
584 shown lower ICCs regardless of study population. On the other hand, contaminants with specific indoor
585 exposure sources, i.e. the flame retardant TDCIPP, and the chemicals related to PCPs, such as parabens and
586 metabolites of DEP and MBzP, showed higher ICCs. This indicates that even for chemicals presenting
587 relatively similar human kinetics, such as BPA and EtP, a substantial difference in ICC can be observed. This
588 is likely due to the more regular or continuous indoor exposure in comparison to erratic diet-related exposure
589 routes and indicates that the exposure route of the respective compound is one of the most important
590 determining factors of temporal variability. However, the potential variation in urinary excretion factors
591 throughout different stages of life for metabolites of AP and PFRs has not been investigated yet.

592 In addition, most of the studies reporting ICCs were conducted on healthy adult populations and/or
593 students, while the studies focused on children were scarce. In the studies on pregnant women, urine
594 samples were usually collected at the time of prenatal checkup visits, hence MV urine was the most common
595 type of collection strategy. Furthermore, the age range in the pregnant women group is not broad and,
596 therefore, the distribution of ICCs in pregnant women is narrower than in adult population.

597

598 **Sampling strategy**

599 Generally, evidence suggests that the use of a single urinary measurement to predict exposure to
600 chemicals with short half-lives may lead to classification errors. The collection of multiple urine samples and
601 the inclusion of information on the sampling strategy, time of collection, and demographic characteristics
602 may provide a more complete approach to assess exposure to various chemicals. However, as shown in
603 Figure 3 and Table S8, only the ICCs of BPA showed a significant improvement from spot sampling to 24 h
604 sampling ($p=0.008$). MeP and OH-MEHP in spot sampling showed borderline significant differences with 24
605 h and MV sampling, respectively (MeP: $p=0.100$; OH-MEHP: $p=0.053$). However, for most chemicals, the
606 ICCs have been similar irrespective of sampling strategies (spot, MV, or 24 h), except BDCIPP. ICCs of BDCIPP
607 were higher for MV sampling compared to spot sampling ($p=0.005$). It should be noted that the divergence
608 in the estimated ICCs for each chemical/metabolite across the studies included in this review could partially
609 be explained by the heterogeneity in the sampling strategy (e.g., sampling frequency and time of collection).
610 Most of the studies did not collect repeated samples within a given day, and thus were unable to properly
611 capture the within-day variability, which may account for the largest proportion of the total variation for
612 many metabolites. Besides, the variation in the ICCs between studies may be partly attributable to
613 differences in the sampling strategy. Because MV samples are more concentrated and the time since the
614 previous void is usually the longest, low molecular phthalate metabolites, such as MEP, MnBP, MiBP, and
615 MBzP had higher reproducibility (higher ICCs, but not statistically significant) in MVs than spot samples
616 (Figure 3). Despite the differences in the procedures of composing pooled samples (e.g. 24 h urine by
617 collecting all complete urine voids over a whole day, or daily pools by combining equal aliquots over urine
618 voids over a whole day) between studies, these pooled samples were grouped under “24 h” regardless of the
619 exact strategy to avoid obtaining too many different types of samples.

620 The differences in the ICCs among various urine collection strategies were mostly determined by the
621 properties of the respective chemicals (Table S8). For example, ICCs of BPA, 3-PBA, and parabens in 24 h
622 urine were higher than in spot urine, while those of phthalate and PFR metabolites were higher in MV urine
623 than in spot urine. Moreover, the variation in the ICCs of 3-PBA was rather wide across the various studies
624 (e.g. ICC 0.13 – 0.80, CRT adjusted 24 h urine). In general, the median ICCs in 24 h urine had a tendency to be
625 slightly higher than for the other two sampling strategies ($p=0.14$; ANOVA). The 24 h urine collection has
626 been suggested as the standard sampling strategy for assessing exposure to environmental pollutants which
627 are eliminated in urine within 24 h (Wang et al., 2016). Indeed, the predictive power of a single spot sample
628 for same-day 24 h urine collection was relatively low for several chemicals (e.g. BPA and PFR metabolites),
629 thereby suggesting that a single spot sample might not be appropriate for substituting the 24 h urine
630 collection. However, the long-term temporal variability of such measurements has not yet been investigated.

631

632 **Influence of correction method**

633 Figure 4 and Table S9 show the variation in the ICCs for chemicals with short half-lives or their
634 metabolites in spot urine between non-adjusted vs CRT-adjusted vs SG-adjusted concentrations. Most of the
635 chemicals with low ICCs (< 0.4) continue to show low reproducibility following adjustment for SG and/or CRT.
636 However, as for EtP and PrP, the distribution of ICCs for CRT-adjusted urine were slightly higher than for non-
637 adjusted urine ($p < 0.2$; Dunn's test). CRT-adjusted ICCs of parabens (MeP, EtP, and PrP) were not significantly
638 different from those of SG adjusted ICCs. On the other hand, CRT-adjusted ICCs of MEP and MEHP were
639 slightly lower than those for SG ($p < 0.5$). According to Table S8, non-adjusted ICCs of MeP, EtP, PrP, MEP,
640 MiBP, MBzP, and BDCIPP showed fair to good median ICCs ($0.40 \geq \text{ICC} > 0.75$), which > 0.4 regardless the
641 dilution adjustment type. This suggests that dilution adjustments of urine concentrations do not significantly
642 affect the ICCs of most of the chemicals included in this review.

643 Data presented in Figure 4 includes all population groups (adults, pregnant women, and children). SG is
644 a measure of the relative density of urine specimens to water and solely depends on the molecular size and
645 weight of analytes in the urine. On the other hand, CRT-correction was more likely to be affected by age,
646 gender, BMI, diet, season and lifestyle variations, which would add other sources of variability, Therefore,
647 the comparisons of ICCs according to CRT-adjustment should have been also stratified by the age group.
648 However, due to limited numbers of studies on each chemical with study population and types of dilution
649 adjustment, we could not consider further statistical analyses. Furthermore, CRT-correction might not be
650 appropriate for some metabolites, because they can be conjugated in the liver as glucuronides or sulfates
651 and are actively excreted by the renal tubules, while CRT is excreted mostly by glomerular filtration. SG is
652 less likely to be influenced by individual phenotype related factors compared to CRT. The results of the
653 comparison also showed that CRT-adjustment slightly improved the ICCs only for EtP and PrP, which suggests
654 that the dilution adjustment did not improve the reproducibility.

655

656 **Exposure sources**

657 The ICCs can be impacted by differences in the exposure sources and routes of various chemicals,
658 between classes, but also within classes for different times and locations of sampling. For example, among
659 the chemical classes targeted in this review, parabens, MEP, MnBP, MiBP, and BDCIPP had higher ICCs
660 compared to the other chemicals. Parabens and low-molecular weight phthalates can be present in PCPs,
661 which are used daily and usually not frequently changed. Depending on the type of PCP, chemicals present
662 in PCPs will absorb through the skin, which is usually less efficient and slower in comparison to e.g. oral
663 exposure. The presence of the stratum corneum is the factor that limits the absorption of chemicals through
664 the skin. This makes the skin a buffer zone that averages the variability of the external exposure, since the
665 absorption rate through the skin might be slower than the dynamics of external exposure changes. This
666 phenomenon can explain the relatively high and reproducible ICCs reported for urinary parabens (2008;
667 Aylward et al., 2020). BDCIPP, For TDCIPP, a flame retardant used in polyurethane foam, the indoor

668 environment is the main exposure source. Since the indoor environment does not change frequently, BDCIPP,
669 a metabolite of TDCIPP, would have relatively constant internal exposure levels, which in turn will result in
670 higher ICCs. On the other hand, for chemicals such as BPA and DEHP metabolites, the main exposure source
671 is the diet, which tends to vary both daily and seasonally, resulting in higher variability and thus lower ICCs.
672 In addition, absorption from the gastrointestinal tract is usually rapid and, in combination with an efficient
673 and fast metabolism and elimination, it contributes to the large variability in the urinary excretion of these
674 metabolites.

675

676 **Overall recommendations**

677 We hypothesized that study population (age group), timing of urine collection, and dilution adjustment
678 will have a significant influence on the ICCs of various chemicals with short-lives. However, the information
679 summarized in Figures 2-4 and in Tables S7-S9, indicates that the variability in urinary concentrations is
680 largely determined by the nature and properties of the measured chemical or its metabolite. Moreover, our
681 comparisons in Tables S7-S9 clearly show that the ICCs (reproducibility) did not dramatically improve
682 according to study population, sampling strategies, or dilution adjustments. However, our comparisons are
683 not restricted to the same study design, but include studies conducted in various study designs. Therefore, it
684 should be kept in mind that the results from our comparisons may differ from similar comparisons restricted
685 to studies with the same study design. For example, neither study population nor dilution correction was
686 considered in Figure 3. Also, the number of the studies with 24 h sampling was limited, and thus the statistical
687 power was not sufficient to make adequate comparisons. Interpretation of Figures 2-4 should be made with
688 caution. Even for chemicals with relatively similar human pharmacokinetics (e.g. BPA and EtP), a substantial
689 difference in the ICCs can be observed, which indicates that the predominant determining factor for the ICCs
690 is the exposure route.

691 Based on the available knowledge, we suggest that, for some chemicals, the reproducibility in the ICCs
692 can be improved by collecting multiple samples per participant within the same day, including MV. In adults,
693 the collection of only MV samples and correcting for urine dilution might be a good and practical alternative
694 for biomonitoring studies investigating exposure to short-lived chemicals, if the collection of multiple
695 samples is not an option. However, in that case, special attention should be paid to biomarkers which have
696 a higher short-term temporal variability or low ICCs, such as DPHP, BPA, MINCH or MEHP. ICCs of PCP-related
697 chemicals, such as parabens, MEP, MiBP, MBzP and BDCIPP had high and reproducible ICCs (ICCs > 0.40).
698 Moreover, restricting the sampling design onto the MV collection would miss or underestimate exposures at
699 other time points, such as the morning use of cosmetics or breakfast/lunch exposures, etc On the other
700 hand, the ICCs of some chemicals (e.g. BPA, 3-PBA) were rather low (ICCs < 0.40) regardless of sampling
701 strategies, dilution adjustments, and study population, meaning that a high variability in the concentrations
702 is observed due to the erratic nature of exposure. Therefore one single spot sample might not capture the

703 variation of such compounds, especially those largely influenced by dietary intake. Yet, extreme
704 concentration values and other influencing factors (such as variable between-day diets) are averaged out in
705 biomonitoring studies with a large number of individuals. Therefore, reports that calculated BPA intake from
706 single spot urine samples of sufficiently large populations are considered good estimations of the average
707 population exposure (Covaci et al., 2015).

708 The collection of 24 h pooled urine or complete voids with the determination of volume for spot samples
709 would allow for more detailed exposure reconstruction by reverse dosimetry. However, this sampling
710 strategy might not be feasible for most studies and a compromise should be sought. It is recommended for
711 the chemicals with lower ICCs that the sampling strategy in future studies is adapted also to the nature and
712 identity of the chemicals which need to be investigated and their characteristics (half-life, metabolism,
713 urinary excretion patterns, etc) and that it includes the collection of MV urine samples and the measurement
714 of specific gravity for concentration-adjustment to minimize temporal variability. Our recommendations may
715 guide researchers to optimize the study design and interpretation of biomonitoring results for future studies,
716 taking into account the reproducibility of each targeted chemical.

717 Lastly, ICCs included in this review are estimated based on mathematically estimated formula, which
718 may sometimes lead to misuses of ICCs in a variety of disciplines, including the evaluation of health
719 measurement scales. Bobbak et al. (2018) suggested the estimation of ICCs using an Bayesian approach with
720 hierarchical regression and variance-function modeling, which leads to estimates that are a better reflection
721 of a measurement scale's reliability, while maintaining ease of interpretation. Although all ICCs in this review
722 have been estimated using the "traditional" assumptions, researchers should take into account the
723 limitations of mathematically estimated ICCs and should carefully interpret the chemical reliability.

724

725 **Acknowledgements**

726 MR and CG acknowledge funding from the University of Antwerp. AK acknowledges the scholarship provided
727 by the project (POWR.03.02.00-00-I026/17-00) co-financed by the European Union through the European
728 Social Fund under the Operational Programme Knowledge Education Development 2014–2020 and a
729 fellowship (BPN/BEK/2021/1/00132/U/00001) funded by the National Agency for Academic Exchange
730 (NAWA) under the Bekker Programme (2021). YAB acknowledges a fellowship from the Japan Society for the
731 Promotion of Science (JSPS) through the Fund for the Promotion of Joint International Research (Fostering
732 Joint International Research (A), grant number 19KK0288).

733

734 **Table 1.** The compound class specific keywords used in literature searches and the resulting number of publications.
735 Common keywords for each search were: urine, variability or variation, and ICC
736

Compounds	Specific key words	Number of publications
Bisphenols	bisphenols or individual compounds or their acronyms (e.g., BPA, BPF, BPS)	21
Pyrethroids	pyrethroids or pyrethroid metabolites	9
Parabens	paraben, parabens or individual compounds	17
Phthalates	phthalates or the acronyms of individual compounds and their metabolites	23
Alternative plasticizers	alternative plasticizers or the acronyms of individual compounds and their metabolites (e.g., TOTM, DINCH, OH-MEHA)	9
Phosphate flame retardants	phosphate flame retardants or the acronyms individual compound and their metabolites (e.g., BDCIPP, DPHP, DNBP, BCEP)	11

737

738

739
740

Table 2. Intraclass correlation coefficients for phthalate metabolites from different studies.


Reference	Sampling region	Sample type	Dilution adjustment	N	Time frame	MEP	cx-MPP	MnBP	MiBP	MBzP	MEHP	oxo-MEHP	OH-MEHP	cx-MEPP
General population: men and/or women														
Hauser et al. 2004	US	Spot	SG	11 ^M	13 weeks	0.43		0.71		0.55	0.54			
Fromme et al. 2007	Germany	MV	CRT	50	1 week			0.45	0.44	0.58	0.34	0.24		
Baird et al. 2010	US	MV	CRT	60 ^F	2 weeks	0.48		0.34		0.53	0.37	0.33		
Peck et al. 2010	US	MV	CRT	45 ^F	3 weeks	0.61		0.55	0.51	0.64	0.22	0.19		
Preau Jr et al. 2010	US	Spot	CRT	8	1 weeks	0.77								
Braun et al. 2012	US	Spot	SG	137	5 weeks	0.56		0.40	0.36	0.35	0.11			
Meeker et al. 2012	US	Spot	-	269	5 weeks	0.49					0.13	0.14		
Frederiksen et al., 2013	Denmark	24 h	-	33 ^M	7 weeks	0.51				0.59	0.19		0.09	
	Denmark	MV	OSM	33 ^M	7 weeks	0.35				0.35	0.23		0.22	
	Denmark	MV	-	33 ^M	7 weeks	0.33				0.31	0.21		0.21	
	Denmark	Spot	OSM	33 ^M	1 week	0.68				0.39	0.51		0.15	
	Denmark	Spot	-	33 ^M	1 week	0.65				0.38	0.37		0.19	
Townsend et al. 2013	US	MV	CRT	80 ^F	104 weeks	0.44		0.45	0.29		0.16	0.46	0.45	0.47
Dewalque et al. 2015	Belgium	Spot	CRT	351	16 weeks	0.55		0.46	0.64	0.37	0.28	0.20	0.20	
Sun et al. 2017	UK	24 h	-	47	13 weeks	0.12		0.14		0.55	0.26	0.00	0.00	0.00
	UK	24 h	CRT	47	13 weeks	0.10		0.18		0.64	0.30	0.00	0.01	0.02
Faÿs et al. 2020	France and Luxembourg	Spot	-	16	26 weeks	0.51				0.48	0.21	0.24	0.24	0.29
Bastiaensen et al. 2020	Belgium	Spot	-	10	5 days	0.46		0.17	0.49	0.55	0.39	0.11	0.16	0.29
	Belgium	Spot	SG	10	5 days	0.59		0.32	0.70	0.72	0.49	0.09	0.19	0.48
	Belgium	Spot	CRT	10	5 days	0.67		0.44	0.75	0.79	0.55	0.23	0.30	0.64
	Belgium	MV	-	10	5 days	0.69		0.30	0.74	0.77	0.60	0.17	0.36	0.44
	Belgium	MV	SG	10	5 days	0.70		0.42	0.81	0.85	0.65	0.21	0.35	0.53
	Belgium	MV	CRT	10	5 days	0.75		0.43	0.79	0.86	0.67	0.44	0.42	0.65

Pregnant women

Adibi et al. 2008	US	Spot	-	28	6 weeks	0.30		0.62	0.54	0.66	0.35	0.34	0.36	0.33
	US	Spot	CRT	28	6 weeks	0.21		0.55	0.48	0.65	0.25	0.22	0.23	0.21
Catonwine et al. 2014	Puerto Rico	Spot	-	139	6 weeks	0.43	0.23	0.41	0.35	0.37	0.35	0.26	0.25	0.20
	Puerto Rico	Spot	SG	139	6 weeks	0.44	0.20	0.44	0.34	0.41	0.36	0.25	0.24	0.19
Ferguson et al. 2014	US	Spot	SG	1181	27 weeks	0.47	0.36	0.57	0.52	0.61	0.30		0.21	0.31
Fisher et al. 2015	Canada	Spot	-	80	24 weeks	0.38	0.21	0.30		0.23	0.16	0.22	0.18	
	Canada	Spot	SG	80	24 weeks	0.38	0.19	0.32		0.24	0.12	0.20	0.15	
	Canada	Spot	-	80	12 weeks	0.34	0.23	0.30		0.23	0.32	0.22	0.18	
	Canada	Spot	SG	80	12 weeks	0.33	0.21	0.35		0.20	0.23	0.20	0.15	
Valvi et al. 2015	Spain	Spot	CRT	391	21 weeks	0.23		0.19	0.20	0.24	0.18	0.07	0.06	0.19
Yazdy et al. 2018	US	MV	SG	19	20 weeks	0.68								
Shin et al. 2019	US	MV	SG	188	3 weeks	0.58	0.08	0.36	0.38	0.60	0.36	0.32		0.37
Philippat et al. 2021	France	Spot	SG	454	28 weeks	0.61		0.58	0.60	0.63	0.42	0.37	0.35	0.39
Children														
Teitelbaum et al. 2008	US	Spot	-	35 ^(6-10y)	26 weeks	0.26	0.21	0.35	0.28	0.62	0.29	0.23	0.24	
	US	Spot	CRT	35 ^(6-10y)	26 weeks	0.18	0.13	0.14	0.21	0.47	0.26	0.19	0.22	
Watkins et al. 2014	US	Spot	-	283 ^(1-5y)	1 year	0.36	0.20			0.26				
	US	Spot	CRT	283 ^(1-5y)	1 year	0.35	0.19			0.25				
	US	Spot	-	136 ^(1-3y)	2 weeks	0.32	0.31			0.34				
	US	Spot	CRT	136 ^(1-3y)	2 weeks	0.29	0.25			0.36				
Casas et al. 2018	Europe	Spot	CRT	152 ^(6-11y)	24 weeks	0.38		0.36	0.52	0.57	0.67	0.69	0.65	0.69

MV - morning void, BV - bedtime void, 24 h - 24 hour pooling of urine samples, CRT - creatinine, SG - specific gravity, OSM - osmolality, N - number of participants, M - male, F - female, 1-3y - 1 to 3 years of age

742 Figure 1: Graphical representation of variance components and the formula used to calculate intraclass correlation coefficients (ICCs).




743

744
$$ICC = \frac{\sigma^2_{between\ indiv.}}{\sigma^2_{total}} = \frac{\sigma^2_{between\ indiv.}}{\sigma^2_{within\ indiv.\ between\ day} + \sigma^2_{with\ indiv.\ with\ day} + \sigma^2_{between\ indiv.}}$$


745

746 Figure 2. Variation in the ICCs for short-lives chemicals or their metabolites of adult study population to pregnant women and children.
 747




748 (A) ICCs of each class of compound; (B) Each class of compound was summarized according to study population.
 749 Boxplots show median and interquartile range, and upper and bottom bars represent max and minimum, respectively. Each dot represents an individual ICC
 750 from the studies included in this review. Selected data is spot/MV and CRT/SG adjustment (excluded 24 h urine and non-adjustment). Y-axis shows the ICCs
 751 of selected studies. X-axis displays short-lives chemicals or their metabolites stratified by study population: adults, pregnant women, and children.
 752

753 Figure 3. Variation in the ICCs for short-lives chemicals or their metabolites in spot urine compared to morning void and 24h urine.
 754



755 (A) ICCs of each class of compound; (B) Each class of compound was summarized according to sampling strategies.
 756 Boxplots show median and interquartile range, and upper and bottom bars represent max and minimum, respectively. Each dot represents an individual ICC
 757 from the studies included in this review. Studies of adults and pregnant women were included (not considering dilution adjustments). Y-axis shows the ICCs
 758 of selected studies. X-axis displays short-lives chemicals or their metabolites stratified by methods of urinary collection.
 759
 760

761 Figure 4. Variation in the ICCs for short-lives chemicals or their metabolites in spot urine between non-adjusted vs creatinine vs specific gravity-normalized
 762 urine concentrations.
 763



764
 765 (A) ICCs of each class of compound; (B) Each class of compound was summarized according to urinary dilution methods.
 766 Boxplots show median and interquartile range, and upper and bottom bars represent max and minimum, respectively. Each dot represents an individual ICC
 767 from the studies included in this review. Studies of adults, pregnant women, and children are included. Y-axis shows the ICCs of selected studies. X-axis displays
 768 short-lives chemicals or their metabolites stratified by urinary dilution adjustments.
 769

770 **References**

- 771 2008. Final Amended Report on the Safety Assessment of Methylparaben, Ethylparaben,
772 Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as
773 used in Cosmetic Products. *International Journal of Toxicology*. 27, 1-82.
- 774 Adibi, J. J., Whyatt, R. M., Williams, P. L., Calafat, A. M., Camann, D., Herrick, R., Nelson, H.,
775 Bhat, H. K., Perera, F. P., Silva, M. J., Hauser, R., 2008. Characterization of phthalate
776 exposure among pregnant women assessed by repeat air and urine samples. *Environ*
777 *Health Perspect*. 116, 467-73.
- 778 Araki, A., Saito, I., Kanazawa, A., Morimoto, K., Nakayama, K., Shibata, E., Tanaka, M.,
779 Takigawa, T., Yoshimura, T., Chikara, H., Saijo, Y., Kishi, R., 2014. Phosphorus flame
780 retardants in indoor dust and their relation to asthma and allergies of inhabitants. *Indoor*
781 *Air*. 24, 3-15.
- 782 Attfield, K. R., Hughes, M. D., Spengler, J. D., Lu, C., 2014. Within- and between-child
783 variation in repeated urinary pesticide metabolite measurements over a 1-year period.
784 *Environmental Health Perspectives*. 122, 201-206.
- 785 Aylward, L., Vilone, G., Cowan-Ellsberry, C., Arnot, J. A., Westgate, J. N., O'Mahony, C., Hays,
786 S. M., 2020. Exposure to selected preservatives in personal care products: case study
787 comparison of exposure models and observational biomonitoring data. *J Expo Sci Environ*
788 *Epidemiol*. 30, 28-41.
- 789 Aylward, L. L., Hays, S. M., Smolders, R., Koch, H. M., Cocker, J., Jones, K., Warren, N., Levy,
790 L., Bevan, R., 2014. Sources of variability in biomarker concentrations. *J Toxicol Environ*
791 *Health B Crit Rev*. 17, 45-61.
- 792 Aylward, L. L., Hays, S. M., Zidek, A., 2017. Variation in urinary spot sample, 24 h samples,
793 and longer-term average urinary concentrations of short-lived environmental chemicals:
794 implications for exposure assessment and reverse dosimetry. *J Expo Sci Environ*
795 *Epidemiol*. 27, 582-590.
- 796 Barkoski, J., Bennett, D., Tancredi, D., Barr, D. B., Elms, W., Hertz-Picciotto, I., 2018.
797 Variability of urinary pesticide metabolite concentrations during pregnancy in the
798 MARBLES Study. *Environmental Research*. 165, 400-409.
- 799 Barr, D. B., Olsson, A. O., Wong, L.-Y., Udunka, S., Baker, S. E., Whitehead, R. D., Magsumbol,
800 M. S., Williams, B. L., Needham, L. L., 2010. Urinary concentrations of metabolites of
801 pyrethroid insecticides in the general U.S. population: National Health and Nutrition
802 Examination Survey 1999–2002. *Environmental Health Perspectives*. 118, 742-748.
- 803 BASF Technical information, Adipate Plasticizers.
- 804 Bastiaensen, M., Gys, C., Malarvannan, G., Fotache, M., Bombeke, J., Ait Bamai, Y., Araki, A.,
805 Covaci, A., 2020a. Short-term temporal variability of urinary biomarkers of
806 organophosphate flame retardants and plasticizers. *Environ Int*. 146, 106147.
- 807 Bastiaensen, M., Malarvannan, G., Gys, C., Ait Bamai, Y., Araki, A., Covaci, A., 2020b.
808 Between- and within-individual variability of urinary phthalate and alternative plasticizer
809 metabolites in spot, morning void and 24-h pooled urine samples. *Environ Res*. 191,
810 110248.
- 811 Błędzka, D., Gromadzińska, J., Wąsowicz, W., 2014. Parabens. From environmental studies to
812 human health. *Environment International*. 67, 27-42.
- 813 Bobak, C. A., Barr, P. J., O'Malley, A. J., 2018. Estimation of an inter-rater intra-class
814 correlation coefficient that overcomes common assumption violations in the assessment
815 of health measurement scales. *BMC Med Res Methodol*. 18, 93.

816 Bradberry, S. M., Cage, S. A., Proudfoot, A. T., Allister Vale, J., 2005. Poisoning due to
817 pyrethroids. *Toxicological Reviews*. 24, 93-106.

818 Braun, J. M., Kalkbrenner, A. E., Calafat, A. M., Bernert, J. T., Ye, X., Silva, M. J., Barr, D. B.,
819 Sathyanarayana, S., Lanphear, B. P., 2011. Variability and predictors of urinary bisphenol
820 A concentrations during pregnancy. *Environ Health Perspect*. 119, 131-7.

821 Braun, J. M., Smith, K. W., Williams, P. L., Calafat, A. M., Berry, K., Ehrlich, S., Hauser, R.,
822 2012. Variability of urinary phthalate metabolite and bisphenol A concentrations before
823 and during pregnancy. *Environ Health Perspect*. 120, 739-45.

824 Buck Louis, G. M., Yeung, E., Kannan, K., Maisog, J., Zhang, C., Grantz, K. L., Sundaram, R.,
825 2019. Patterns and Variability of Endocrine-disrupting Chemicals During Pregnancy:
826 Implications for Understanding the Exposome of Normal Pregnancy. *Epidemiology*. 30
827 Suppl 2, S65-S75.

828 Bui, T. T., Xu, F., Van den Eede, N., Cousins, A. P., Covaci, A., Cousins, I. T., 2017. Probing the
829 relationship between external and internal human exposure of organophosphate flame
830 retardants using pharmacokinetic modelling. *Environ Pollut*. 230, 550-560.

831 Canada, H., Fifth Report on Human Biomonitoring of Environmental Chemicals in Canada
832 (2019). 2019, pp. 1-463.

833 Cantonwine, D. E., Cordero, J. F., Rivera-Gonzalez, L. O., Anzalota Del Toro, L. V., Ferguson, K.
834 K., Mukherjee, B., Calafat, A. M., Crespo, N., Jimenez-Velez, B., Padilla, I. Y., Alshwabkeh,
835 A. N., Meeker, J. D., 2014. Urinary phthalate metabolite concentrations among pregnant
836 women in Northern Puerto Rico: distribution, temporal variability, and predictors. *Environ*
837 *Int*. 62, 1-11.

838 Casas, M., Basagaña, X., Sakhi, A. K., Haug, L. S., Philippat, C., Granum, B., Manzano-Salgado,
839 C. B., Brochot, C., Zeman, F., de Bont, J., Andrusaityte, S., Chatzi, L., Donaire-Gonzalez, D.,
840 Giorgis-Allemand, L., Gonzalez, J. R., Gracia-Lavedan, E., Grazuleviciene, R., Kampouri, M.,
841 Lyon-Caen, S., Pañella, P., Petraviciene, I., Robinson, O., Urquiza, J., Vafeiadi, M., Vernet,
842 C., Waiblinger, D., Wright, J., Thomsen, C., Slama, R., Vrijheid, M., 2018. Variability of
843 urinary concentrations of non-persistent chemicals in pregnant women and school-aged
844 children. *Environment International*. 121, 561-573.

845 Chang, W. H., Herianto, S., Lee, C. C., Hung, H., Chen, H. L., 2021. The effects of phthalate
846 ester exposure on human health: A review. *Sci Total Environ*. 786, 147371.

847 Cheung, K. L., Lafayette, R. A., 2013. Renal physiology of pregnancy. *Adv Chronic Kidney Dis*.
848 20, 209-14.

849 Christensen KL, Lorber M, Koch HM, Kolossa-Gehring M, Morgan MK. 2019, Population variability of
850 phthalate metabolites and bisphenol A concentrations in spot urine samples versus 24- or 48-h
851 collections. *J Expo Sci Environ Epidemiol*. 22(6), 632-640

852 Chung, M. K., Buck Louis, G. M., Kannan, K., Patel, C. J., 2019. Exposome-wide association
853 study of semen quality: Systematic discovery of endocrine disrupting chemical biomarkers
854 in fertility require large sample sizes. *Environ Int*. 125, 505-514.

855 Covaci, A., Den Hond, E., Geens, T., Govarts, E., Koppen, G., Frederiksen, H., Knudsen, L. E.,
856 Morck, T. A., Gutleb, A. C., Guignard, C., Cocco, E., Horvat, M., Heath, E., Kosjek, T., Mazej,
857 D., Tratnik, J. S., Castano, A., Esteban, M., Cutanda, F., Ramos, J. J., Berglund, M., Larsson,
858 K., Jonsson, B. A., Biot, P., Casteleyn, L., Joas, R., Joas, A., Bloemen, L., Sepai, O., Exley, K.,
859 Schoeters, G., Angerer, J., Kolossa-Gehring, M., Fiddicke, U., Aerts, D., Koch, H. M., 2015.
860 Urinary BPA measurements in children and mothers from six European member states:
861 Overall results and determinants of exposure. *Environ Res*. 141, 77-85.

862 Derakhshan, A., Shu, H., Broeren, M. A. C., Lindh, C. H., Peeters, R. P., Kortenkamp, A.,
863 Demeneix, B., Bornehag, C. G., Korevaar, T. I. M., 2021. Association of phthalate exposure
864 with thyroid function during pregnancy. *Environ Int.* 157, 106795.
865 Dewalque, L., Pirard, C., Vandepaer, S., Charlier, C., 2015. Temporal variability of urinary
866 concentrations of phthalate metabolites, parabens and benzophenone-3 in a Belgian
867 adult population. *Environmental Research.* 142, 414-423.
868 ECHA, 2012. Evaluation of new scientific evidence concerning DINP and DIDP In relation to
869 entry 52 of Annex XVII to REACH Regulation (EC) No 1907/2006 Final review report.
870 European chemicals agency.
871 Engel, L. S., Buckley, J. P., Yang, G., Liao, L. M., Satagopan, J., Calafat, A. M., Matthews, C. E.,
872 Cai, Q., Ji, B. T., Cai, H., Engel, S. M., Wolff, M. S., Rothman, N., Zheng, W., Xiang, Y. B.,
873 Shu, X. O., Gao, Y. T., Chow, W. H., 2014. Predictors and variability of repeat
874 measurements of urinary phenols and parabens in a cohort of Shanghai women and men.
875 *Environmental Health Perspectives.* 122, 733-740.
876 European Food Safety Authority, E., 2015. Scientific Opinion on the risks to public health
877 related to the presence of bisphenol A (BPA) in foodstuffs: Executive summary. *EFSA*
878 *Journal.* 13.
879 Faÿs, F., Palazzi, P., Hardy, E. M., Schaeffer, C., Phillipat, C., Zeimet, E., Vaillant, M.,
880 Beausoleil, C., Rousselle, C., Slama, R., Appenzeller, B. M. R., 2020. Is there an optimal
881 sampling time and number of samples for assessing exposure to fast elimination
882 endocrine disruptors with urinary biomarkers? *Science of the Total Environment.* 747,
883 141185-141185.
884 Faÿs, F., Hardy, E. M., Palazzi, P., Haan, S., Beausoleil, C., Appenzeller, B. M. R., 2021.
885 Biomonitoring of fast-elimination endocrine disruptors - Results from a 6-month follow
886 up on human volunteers with repeated urine and hair collection. *Sci Total Environ.* 778,
887 146330.
888 Fisher, M., Arbuckle, T. E., Mallick, R., LeBlanc, A., Hauser, R., Feeley, M., Koniecki, D.,
889 Ramsay, T., Provencher, G., Berube, R., Walker, M., 2015. Bisphenol A and phthalate
890 metabolite urinary concentrations: Daily and across pregnancy variability. *J Expo Sci*
891 *Environ Epidemiol.* 25, 231-9.
892 Frederiksen, H., Kranich, S. K., Jorgensen, N., Taboureau, O., Petersen, J. H., Andersson, A.
893 M., 2013. Temporal variability in urinary phthalate metabolite excretion based on spot,
894 morning, and 24-h urine samples: considerations for epidemiological studies. *Environ Sci*
895 *Technol.* 47, 958-67.
896 Frederiksen, H., Nielsen, O., Koch, H. M., Skakkebaek, N. E., Juul, A., Jorgensen, N.,
897 Andersson, A. M., 2020. Changes in urinary excretion of phthalates, phthalate substitutes,
898 bisphenols and other polychlorinated and phenolic substances in young Danish men;
899 2009-2017. *Int J Hyg Environ Health.* 223, 93-105.
900 Fromme, H., Bolte, G., Koch, H. M., Angerer, J., Boehmer, S., Drexler, H., Mayer, R., Liebl, B.,
901 2007. Occurrence and daily variation of phthalate metabolites in the urine of an adult
902 population. *Int J Hyg Environ Health.* 210, 21-33.
903 Garí, M., González-Quinteiro, Y., Bravo, N., Grimalt, J. O., 2018. Analysis of metabolites of
904 organophosphate and pyrethroid pesticides in human urine from urban and agricultural
905 populations (Catalonia and Galicia). *Science of The Total Environment.* 622-623, 526-533.
906 Geens, T., Aerts, D., Berthot, C., Bourguignon, J. P., Goeyens, L., Lecomte, P., Maghuin-
907 Rogister, G., Pironnet, A. M., Pussemier, L., Scippo, M. L., Van Loco, J., Covaci, A., 2012. A

908 review of dietary and non-dietary exposure to bisphenol-A. *Food Chem Toxicol.* 50, 3725-
909 40.

910 Guidry, V. T., Longnecker, M. P., Aase, H., Eggesbø, M., Zeiner, P., Reichborn-Kjennerud, T.,
911 Knudsen, G. P., Bertelsen, R. J., Ye, X., Calafat, A. M., Engel, S. M., 2015. Measurement of
912 Total and Free Urinary Phenol and Paraben Concentrations over the Course of Pregnancy:
913 Assessing Reliability and Contamination of Specimens in the Norwegian Mother and Child
914 Cohort Study. *Environmental Health Perspectives.* 123, 705-711.

915 Guo, Y., Wang, L., Kannan, K., 2013. Phthalates and Parabens in Personal Care Products From
916 China: Concentrations and Human Exposure. *Archives of Environmental Contamination
917 and Toxicology* 2013 66:1. 66, 113-119.

918 Gyllenhammar, I., Glynn, A., Jonsson, B. A., Lindh, C. H., Darnerud, P. O., Svensson, K., Lignell,
919 S., 2017. Diverging temporal trends of human exposure to bisphenols and plastizisers,
920 such as phthalates, caused by substitution of legacy EDCs? *Environ Res.* 153, 48-54.

921 Gys, C., Ait Bamai, Y., Araki, A., Bastiaensen, M., Caballero-Casero, N., Kishi, R., Covaci, A.,
922 2020. Biomonitoring and temporal trends of bisphenols exposure in Japanese school
923 children. *Environmental Research.* 191, 110172.

924 Gys, C., Bastiaensen, M., Bruckers, L., Colles, A., Govarts, E., Martin, L. R., Verheyen, V.,
925 Koppen, G., Morrens, B., Den Hond, E., De Decker, A., Schoeters, G., Covaci, A., 2021a.
926 Determinants of exposure levels of bisphenols in flemish adolescents. *Environmental
927 Research.* 193, 110567.

928 Gys, C., Bastiaensen, M., Malarvannan, G., Ait Bamai, Y., Araki, A., Covaci, A., 2021b. Short-
929 term variability of bisphenols in spot, morning void and 24-hour urine samples.
930 *Environmental Pollution.* 268, 115747.

931 Hbm4Eu, Second list of HBM4EU priority substances and Chemical Substance Group Leaders
932 for 2019-2021 Deliverable Report D 4.5 WP 4-Prioritisation and input to the Annual Work
933 Plan. 2018.

934 Heffernan, A. L., Aylward, L. L., Toms, L. M., Sly, P. D., Macleod, M., Mueller, J. F., 2014.
935 Pooled biological specimens for human biomonitoring of environmental chemicals:
936 opportunities and limitations. *J Expo Sci Environ Epidemiol.* 24, 225-32.

937 Hoffman, K., Butt, C. M., Chen, A., Limkakeng, A. T., Jr., Stapleton, H. M., 2015. High
938 Exposure to Organophosphate Flame Retardants in Infants: Associations with Baby
939 Products. *Environ Sci Technol.* 49, 14554-9.

940 Hoffman, K., Daniels, J. L., Stapleton, H. M., 2014. Urinary metabolites of organophosphate
941 flame retardants and their variability in pregnant women. *Environ Int.* 63, 169-72.

942 Hoffman, K., Lorenzo, A., Butt, C. M., Adair, L., Herring, A. H., Stapleton, H. M., Daniels, J. L.,
943 2017. Predictors of urinary flame retardant concentration among pregnant women.
944 *Environ Int.* 98, 96-101.

945 Hou, M., Shi, Y., Jin, Q., Cai, Y., 2020. Organophosphate esters and their metabolites in
946 paired human whole blood, serum, and urine as biomarkers of exposure. *Environ Int.* 139,
947 105698.

948 Hou, R., Xu, Y., Wang, Z., 2016. Review of OPFRs in animals and humans: Absorption,
949 bioaccumulation, metabolism, and internal exposure research. *Chemosphere.* 153, 78-90.

950 Huang, K., Zhang, X., Wang, B., Wang, X., You, Y., Tang, H., He, J., Xu, S., Zheng, L., Zhou, Y.,
951 Mao, Z., Jing, T., 2021. Accurate assessment of parabens exposure in healthy Chinese
952 female adults: Findings from a multi-pathway exposure assessment coupled with
953 intervention study. *Environmental Research.* 193, 110540-110540.

954 Jurewicz, J., Radwan, M., Wielgomas, B., Karwacka, A., Klimowska, A., Kałużny, P., Radwan,
955 P., Hanke, W., 2020a. Parameters of ovarian reserve in relation to urinary concentrations
956 of parabens. *Environmental Health: A Global Access Science Source*. 19.

957 Jurewicz, J., Radwan, M., Wielgomas, B., Sobala, W., Piskunowicz, M., Radwan, P., Bochenek,
958 M., Hanke, W., 2015. The effect of environmental exposure to pyrethroids and DNA
959 damage in human sperm. *Systems Biology in Reproductive Medicine*. 61, 37-43.

960 Jurewicz, J., Radwan, P., Wielgomas, B., Radwan, M., Karwacka, A., Kałużny, P., Piskunowicz,
961 M., Dziewirska, E., Hanke, W., 2020b. Exposure to pyrethroid pesticides and ovarian
962 reserve. *Environment International*. 144, 106028-106028.

963 Jusko, T. A., Shaw, P. A., Snijder, C. A., Pierik, F. H., Koch, H. M., Hauser, R., Jaddoe, V. W.,
964 Burdorf, A., Hofman, A., Tiemeier, H., Longnecker, M. P., 2014. Reproducibility of urinary
965 bisphenol A concentrations measured during pregnancy in the Generation R Study. *J Expo
966 Sci Environ Epidemiol*. 24, 532-6.

967 Kaneko, H., *Pyrethroid Chemistry and Metabolism*. Hayes' Handbook of Pesticide Toxicology.
968 Elsevier Inc., 2010, pp. 1635-1663.

969 Kawamura, Y., Etoh, M., Hirakawa, Y., Abe, Y., Mutsuga, M., 2014. Bisphenol A in domestic
970 and imported canned foods in Japan. *Food Addit Contam Part A Chem Anal Control Expo
971 Risk Assess*. 31, 330-40.

972 Khmiri, I., Côté, J., Mantha, M., Khemiri, R., Lacroix, M., Gely, C., Toutain, P.-L., Picard-Hagen,
973 N., Gayraud, V., Bouchard, M., 2020. Toxicokinetics of bisphenol-S and its glucuronide in
974 plasma and urine following oral and dermal exposure in volunteers for the interpretation
975 of biomonitoring data. *Environment International*. 138, 105644.

976 Kim, H., Rebholz, C. M., Wong, E., Buckley, J. P., 2020a. Urinary organophosphate ester
977 concentrations in relation to ultra-processed food consumption in the general US
978 population. *Environ Res*. 182, 109070.

979 Kim, J. H., Kang, D. R., Kwak, J. M., Lee, J. K., 2020b. Concentration and Variability of Urinary
980 Phthalate Metabolites, Bisphenol A, Triclosan, and Parabens in Korean Mother–Infant
981 Pairs. *Sustainability 2020*, Vol. 12, Page 8516. 12, 8516-8516.

982 Klimowska, A., Amenda, K., Rodzaj, W., Wileńska, M., Jurewicz, J., Wielgomas, B., 2020.
983 Evaluation of 1-year urinary excretion of eight metabolites of synthetic pyrethroids,
984 chlorpyrifos, and neonicotinoids. *Environment International*. 145, 106119-106119.

985 Koch, H. M., Angerer, J., 2007. Di-iso-nonylphthalate (DINP) metabolites in human urine
986 after a single oral dose of deuterium-labelled DINP. *Int J Hyg Environ Health*. 210, 9-19.

987 Koch, H. M., Aylward, L. L., Hays, S. M., Smolders, R., Moos, R. K., Cocker, J., Jones, K.,
988 Warren, N., Levy, L., Bevan, R., 2014. Inter- and intra-individual variation in urinary
989 biomarker concentrations over a 6-day sampling period. Part 2: Personal care product
990 ingredients. *Toxicology Letters*. 231, 261-269.

991 Koch, H. M., Bolt, H. M., Angerer, J., 2004. Di(2-ethylhexyl)phthalate (DEHP) metabolites in
992 human urine and serum after a single oral dose of deuterium-labelled DEHP. *Arch Toxicol*.
993 78, 123-30.

994 Koch, H. M., Christensen, K. L., Harth, V., Lorber, M., Bruning, T., 2012. Di-n-butyl phthalate
995 (DnBP) and diisobutyl phthalate (DiBP) metabolism in a human volunteer after single oral
996 doses. *Arch Toxicol*. 86, 1829-39.

997 Koch, H. M., Schutze, A., Palmke, C., Angerer, J., Bruning, T., 2013. Metabolism of the
998 plasticizer and phthalate substitute diisononyl-cyclohexane-1,2-dicarboxylate
999 (DINCH((R))) in humans after single oral doses. *Arch Toxicol*. 87, 799-806.

1000 Kovačič, A., Gys, C., Gulin, M. R., Kosjek, T., Heath, D., Covaci, A., Heath, E., 2020. The
1001 migration of bisphenols from beverage cans and reusable sports bottles. *Food Chemistry*.
1002 331, 127326.

1003 Lassen, T. H., Frederiksen, H., Jensen, T. K., Petersen, J. H., Main, K. M., Skakkebaek, N. E.,
1004 Jorgensen, N., Kranich, S. K., Andersson, A. M., 2013. Temporal variability in urinary
1005 excretion of bisphenol A and seven other phenols in spot, morning, and 24-h urine
1006 samples. *Environ Res*. 126, 164-70.

1007 Lee, G., Kim, S., Park, H., Lee, J., Lee, J. P., Kho, Y., Choi, G., Park, J., Worakhunpiset, S.,
1008 Moon, H. B., Choi, K., 2021. Variability of urinary creatinine, specific gravity, and
1009 osmolality over the course of pregnancy: Implications in exposure assessment among
1010 pregnant women. *Environ Res*. 198, 110473.

1011 Leng, G., Koch, H. M., Gries, W., Schutze, A., Langsch, A., Bruning, T., Otter, R., 2014. Urinary
1012 metabolite excretion after oral dosage of bis(2-propylheptyl) phthalate (DHPH) to five
1013 male volunteers--characterization of suitable biomarkers for human biomonitoring.
1014 *Toxicol Lett*. 231, 282-8.

1015 Lessmann, F., Bury, D., Weiss, T., Hayen, H., Bruning, T., Koch, H. M., 2018. De-novo
1016 identification of specific exposure biomarkers of the alternative plasticizer di(2-
1017 ethylhexyl) terephthalate (DEHTP) after low oral dosage to male volunteers by HPLC-Q-
1018 Orbitrap-MS. *Biomarkers*. 23, 196-206.

1019 Li, A. J., Martinez-Moral, M. P., Kannan, K., 2019a. Temporal variability in urinary pesticide
1020 concentrations in repeated-spot and first-morning-void samples and its association with
1021 oxidative stress in healthy individuals. *Environment International*. 130, 104904-104904.

1022 Li, J., Liu, W., Xia, W., Zhao, H., Zhou, Y., Li, Y., Wu, C., Liu, H., Zhang, B., Zhu, Y., Hu, J., Wang,
1023 X., Ye, D., Xu, S., Cai, Z., 2019b. Variations, Determinants, and Coexposure Patterns of
1024 Personal Care Product Chemicals among Chinese Pregnant Women: A Longitudinal Study.
1025 *Environmental Science & Technology*. 53, 6546-6555.

1026 Liao, C., Kannan, K., 2011. Widespread occurrence of bisphenol A in paper and paper
1027 products: implications for human exposure. *Environ Sci Technol*. 45, 9372-9.

1028 Lin, X., Pan, W., Liu, J., 2021. Variability of urinary pyrethroid biomarkers in Chinese young-
1029 aged men and women over one year. *Environmental Pollution*. 269, 116155-116155.

1030 Long, S. E., Kahn, L. G., Trasande, L., Jacobson, M. H., 2021. Urinary phthalate metabolites
1031 and alternatives and serum sex steroid hormones among pre- and postmenopausal
1032 women from NHANES, 2013-16. *Sci Total Environ*. 769, 144560.

1033 Malveda, M., Sesto, B., Passararat, S., Zhang, V., Plasticizers. IHS Markit Ltd., 2018.

1034 Meeker, J. D., Barr, D. B., Hauser, R., 2008. Human semen quality and sperm DNA damage in
1035 relation to urinary metabolites of pyrethroid insecticides. *Human reproduction (Oxford,*
1036 *England)*. 23, 1932-1940.

1037 Meeker, J. D., Barr, D. B., Hauser, R., 2009. Pyrethroid insecticide metabolites are associated
1038 with serum hormone levels in adult men. *Reproductive Toxicology*. 27, 155-160.

1039 Meeker, J. D., Cantonwine, D. E., Rivera-González, L. O., Ferguson, K. K., Mukherjee, B.,
1040 Calafat, A. M., Ye, X., Anzalota Del Toro, L. V., Crespo-Hernández, N., Jiménez-Vélez, B.,
1041 Alshawabkeh, A. N., Cordero, J. F., 2013a. Distribution, Variability, and Predictors of
1042 Urinary Concentrations of Phenols and Parabens among Pregnant Women in Puerto Rico.
1043 *Environmental Science & Technology*. 47, 3439-3447.

1044 Meeker, J. D., Cooper, E. M., Stapleton, H. M., Hauser, R., 2013b. Urinary metabolites of
1045 organophosphate flame retardants: temporal variability and correlations with house dust
1046 concentrations. *Environ Health Perspect*. 121, 580-5.

1047 Moos, R. K., Angerer, J., Dierkes, G., Brüning, T., Koch, H. M., 2016. Metabolism and
1048 elimination of methyl, iso- and n-butyl paraben in human urine after single oral dosage.
1049 Archives of Toxicology. 90, 2699-2709.

1050 Moos, R. K., Koch, H. M., Angerer, J., Apel, P., Schröter-Kermani, C., Brüning, T., Kolossa-
1051 Gehring, M., 2015. Parabens in 24h urine samples of the German Environmental
1052 Specimen Bank from 1995 to 2012. International Journal of Hygiene and Environmental
1053 Health. 218, 666-674.

1054 Morgan, M. K., Nash, M., Barr, D. B., Starr, J. M., Scott Clifton, M., Sobus, J. R., 2018.
1055 Distribution, variability, and predictors of urinary bisphenol A levels in 50 North Carolina
1056 adults over a six-week monitoring period. Environ Int. 112, 85-99.

1057 Morgan, M. K., Sheldon, L. S., Croghan, C. W., Jones, P. A., Chuang, J. C., Wilson, N. K., 2007.
1058 An observational study of 127 preschool children at their homes and daycare centers in
1059 Ohio: Environmental pathways to cis- and trans-permethrin exposure. Environmental
1060 Research. 104, 266-274.

1061 Morgan, M. K., Sobus, J. R., Barr, D. B., Croghan, C. W., Chen, F. L., Walker, R., Alston, L.,
1062 Andersen, E., Clifton, M. S., 2016. Temporal variability of pyrethroid metabolite levels in
1063 bedtime, morning, and 24-h urine samples for 50 adults in North Carolina. Environmental
1064 Research. 144, 81-91.

1065 Nehring, A., Bury, D., Ringbeck, B., Kling, H. W., Otter, R., Weiss, T., Brüning, T., Koch, H. M.,
1066 2020. Metabolism and urinary excretion kinetics of di(2-ethylhexyl) adipate (DEHA) in
1067 four human volunteers after a single oral dose. Toxicol Lett. 321, 95-102.

1068 Nishihama, Y., Ameda, R., Yoshinaga, J., Konishi, S., Yoneyama, M., Nakajima, D., Shiraishi,
1069 H., Imai, H., 2018. Inter- and intra-individual variation in urinary concentrations of
1070 parabens in male and female Japanese subjects. Journal of Environmental Science and
1071 Health, Part A. 53, 73-78.

1072 Oh, J., Choi, J. W., Ahn, Y. A., Kim, S., 2018. Pharmacokinetics of bisphenol S in humans after
1073 single oral administration. Environ Int. 112, 127-133.

1074 Oulhote, Y., Bouchard, M. F., 2013. Urinary Metabolites of Organophosphate and Pyrethroid
1075 Pesticides and Behavioral Problems in Canadian Children. Environmental Health
1076 Perspectives. 121, 1378-1384.

1077 Percy, Z., Vuong, A. M., Ospina, M., Calafat, A. M., La Guardia, M. J., Xu, Y., Hale, R. C.,
1078 Dietrich, K. N., Xie, C., Lanphear, B. P., Braun, J. M., Cecil, K. M., Yolton, K., Chen, A., 2020.
1079 Organophosphate esters in a cohort of pregnant women: Variability and predictors of
1080 exposure. Environ Res. 184, 109255.

1081 Philippat, C., Wolff, M. S., Calafat, A. M., Ye, X., Bausell, R., Meadows, M., Stone, J., Slama, R.,
1082 Engel, S. M., 2013. Prenatal Exposure to Environmental Phenols: Concentrations in
1083 Amniotic Fluid and Variability in Urinary Concentrations during Pregnancy. Environmental
1084 Health Perspectives. 121, 1225-1231.

1085 Pleil, J. D., Sobus, J. R., 2013. Estimating lifetime risk from spot biomarker data and intraclass
1086 correlation coefficients (ICC). Journal of Toxicology and Environmental Health - Part A:
1087 Current Issues. 76, 747-766.

1088 Pleil, J. D., Wallace, M. A. G., Stiegel, M. A., Funk, W. E., 2018. Human biomarker
1089 interpretation: the importance of intra-class correlation coefficients (ICC) and their
1090 calculations based on mixed models, ANOVA, and variance estimates.
1091 <https://doi.org/10.1080/10937404.2018.1490128>. 21, 161-180.

1092 Pollack, A. Z., Mumford, S. L., Krall, J. R., Carmichael, A. E., Sjaarda, L. A., Perkins, N. J.,
1093 Kannan, K., Schisterman, E. F., 2018. Exposure to bisphenol A, chlorophenols,

1094 benzophenones, and parabens in relation to reproductive hormones in healthy women: A
1095 chemical mixture approach. *Environment International*. 120, 137-144.

1096 Pollack, A. Z., Perkins, N. J., Sjaarda, L., Mumford, S. L., Kannan, K., Philippat, C., Wactawski-
1097 Wende, J., Schisterman, E. F., 2016. Variability and exposure classification of urinary
1098 phenol and paraben metabolite concentrations in reproductive-aged women.
1099 *Environmental Research*. 151, 513-520.

1100 Poma, G., Glynn, A., Malarvannan, G., Covaci, A., Darnerud, P. O., 2017. Dietary intake of
1101 phosphorus flame retardants (PFRs) using Swedish food market basket estimations. *Food
1102 Chem Toxicol*. 100, 1-7.

1103 Poma, G., Sales, C., Bruyland, B., Christia, C., Gosciny, S., Van Loco, J., Covaci, A., 2018.
1104 Occurrence of Organophosphorus Flame Retardants and Plasticizers (PFRs) in Belgian
1105 Foodstuffs and Estimation of the Dietary Exposure of the Adult Population. *Environ Sci
1106 Technol*. 52, 2331-2338.

1107 Preau JL Jr, Wong LY, Silva MJ, Needham LL, Calafat AM., 2010. Variability over 1 week in the urinary
1108 concentrations of metabolites of diethyl phthalate and di(2-ethylhexyl) phthalate among eight
1109 adults: an observational study *Environ Health Perspect*. 118(12), 1748-1754.

1110 Radwan, M., Jurewicz, J., Wielgomas, B., Piskunowicz, M., Sobala, W., Radwan, P.,
1111 Jakubowski, L., Hawuła, W., Hanke, W., 2015. The association between environmental
1112 exposure to pyrethroids and sperm aneuploidy. *Chemosphere*. 128, 42-48.

1113 Ratelle, M., Coté, J., Bouchard, M., 2015a. Time profiles and toxicokinetic parameters of key
1114 biomarkers of exposure to cypermethrin in orally exposed volunteers compared with
1115 previously available kinetic data following permethrin exposure. *Journal of Applied
1116 Toxicology*. 35, 1586-1593.

1117 Ratelle, M., Côté, J., Bouchard, M., 2015b. Toxicokinetics of permethrin biomarkers of
1118 exposure in orally exposed volunteers. *Toxicology letters*. 232, 369-375.

1119 REACH, Commission Regulation (EU) 2018/2005 of 17 December 2018 amending Annex XVII
1120 to Regulation (EC) No 1907/2006 of the European Parliament and of the Council
1121 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals
1122 (REACH) as regards bis(2-ethylhexyl) phthalate (DEHP), dibutyl phthalate (DBP), benzyl
1123 butyl phthalate (BBP) and diisobutyl phthalate (DIBP) (Text with EEA relevance.). 2018,
1124 pp. 14-19.

1125 Rodzaj, W., Wileńska, M., Klimowska, A., Dziewirska, E., Jurewicz, J., Walczak-Jędrzejowska,
1126 R., Słowikowska-Hilczler, J., Hanke, W., Wielgomas, B., 2021. Concentrations of urinary
1127 biomarkers and predictors of exposure to pyrethroid insecticides in young, Polish, urban-
1128 dwelling men. *Science of The Total Environment*. 773, 145666-145666.

1129 Romano, M. E., Hawley, N. L., Eliot, M., Calafat, A. M., Jayatilaka, N. K., Kelsey, K., McGarvey,
1130 S., Phipps, M. G., Savitz, D. A., Werner, E. F., Braun, J. M., 2017. Variability and predictors
1131 of urinary concentrations of organophosphate flame retardant metabolites among
1132 pregnant women in Rhode Island. *Environ Health*. 16, 40.

1133 Rosner, B., 2010. *fundamentals of biostatistics*.

1134 Sakhi, A. K., Sabaredzovic, A., Papadopoulou, E., Cequier, E., Thomsen, C., 2018. Levels,
1135 variability and determinants of environmental phenols in pairs of Norwegian mothers and
1136 children. *Environment International*. 114, 242-251.

1137 Sams, C., Jones, K., 2012. Biological monitoring for exposure to deltamethrin: A human oral
1138 dosing study and background levels in the UK general population. *Toxicology Letters*. 213,
1139 35-38.

1140 ScCs, Opinion on parabens (SCCS/1348/10). 2011.

1141 ScCs, Opinion on Propylparaben (SCCS/1623/20). SCCS, 2021.

1142 Shin, M.-Y., Shin, C., Choi, J. W., Lee, J., Lee, S., Kim, S., 2019. Pharmacokinetic profile of
1143 propyl paraben in humans after oral administration. *Environment International*. 130,
1144 104917-104917.

1145 Smarr, M. M., Sundaram, R., Honda, M., Kannan, K., Louis, G. M. B., 2017. Urinary
1146 Concentrations of Parabens and Other Antimicrobial Chemicals and Their Association with
1147 Couples' Fecundity. *Environmental Health Perspectives*. 125, 730-736.

1148 Smith, K. W., Braun, J. M., Williams, P. L., Ehrlich, S., Correia, K. F., Calafat, A. M., Ye, X., Ford,
1149 J., Keller, M., Meeker, J. D., Hauser, R., 2012. Predictors and variability of urinary paraben
1150 concentrations in men and women, including before and during pregnancy.
1151 *Environmental Health Perspectives*. 120, 1538-1543.

1152 Soni, M. G., Carabin, I. G., Burdock, G. A., 2005. Safety assessment of esters of p-
1153 hydroxybenzoic acid (parabens). *Food and Chemical Toxicology*. 43, 985-1015.

1154 Stacy, S. L., Eliot, M., Calafat, A. M., Chen, A., Lanphear, B. P., Hauser, R., Papandonatos, G.
1155 D., Sathyanarayana, S., Ye, X., Yolton, K., Braun, J. M., 2016. Patterns, Variability, and
1156 Predictors of Urinary Bisphenol A Concentrations during Childhood. *Environ Sci Technol*.
1157 50, 5981-90.

1158 Teeguarden, J. G., Twaddle, N. C., Churchwell, M. I., Yang, X., Fisher, J. W., Seryak, L. M.,
1159 Doerge, D. R., 2015. 24-hour human urine and serum profiles of bisphenol A following
1160 ingestion in soup: Individual pharmacokinetic data and emographics. *Data Brief*. 4, 83-6.

1161 Teitelbaum, S. L., Britton, J. A., Calafat, A. M., Ye, X., Silva, M. J., Reidy, J. A., Galvez, M. P.,
1162 Brenner, B. L., Wolff, M. S., 2008. Temporal variability in urinary concentrations of
1163 phthalate metabolites, phytoestrogens and phenols among minority children in the
1164 United States. *Environ Res*. 106, 257-69.

1165 Thayer, K. A., Doerge, D. R., Hunt, D., Schurman, S. H., Twaddle, N. C., Churchwell, M. I.,
1166 Garantziotis, S., Kissling, G. E., Easterling, M. R., Bucher, J. R., Birnbaum, L. S., 2015.
1167 Pharmacokinetics of bisphenol A in humans following a single oral administration. *Environ*
1168 *Int*. 83, 107-15.

1169 Townsend, M. K., Franke, A. A., Li, X., Within-person reproducibility of urinary bisphenol A
1170 and phthalate metabolites over a 1 to 3 year period among women in the Nurses' Health
1171 Studies: a prospective cohort study. 2013.

1172 Valvi, D., Monfort, N., Ventura, R., Casas, M., Casas, L., Sunyer, J., Vrijheid, M., 2015.
1173 Variability and predictors of urinary phthalate metabolites in Spanish pregnant women.
1174 *Int J Hyg Environ Health*. 218, 220-31.

1175 Van den Eede, N., Heffernan, A. L., Aylward, L. L., Hobson, P., Neels, H., Mueller, J. F., Covaci,
1176 A., 2015. Age as a determinant of phosphate flame retardant exposure of the Australian
1177 population and identification of novel urinary PFR metabolites. *Environ Int*. 74, 1-8.

1178 van der Meer, T. P., Chung, M. K., van Faassen, M., Makris, K. C., van Beek, A. P., Kema, I. P.,
1179 Wolffenbuttel, B. H. R., van Vliet-Ostapchouk, J. V., Patel, C. J., 2021. Temporal exposure
1180 and consistency of endocrine disrupting chemicals in a longitudinal study of individuals
1181 with impaired fasting glucose. *Environmental Research*. 197, 110901-110901.

1182 van der Veen, I., de Boer, J., 2012. Phosphorus flame retardants: properties, production,
1183 environmental occurrence, toxicity and analysis. *Chemosphere*. 88, 1119-53.

1184 van Wendel de Joode, B., Mora, A. M., Lindh, C. H., Hernández-Bonilla, D., Córdoba, L.,
1185 Wesseling, C., Hoppin, J. A., Mergler, D., 2016. Pesticide exposure and neurodevelopment
1186 in children aged 6–9 years from Talamanca, Costa Rica. *Cortex*. 85, 137-150.

1187 Vernet, C., Philippat, C., Calafat, A. M., Ye, X., Lyon-Caen, S., Siroux, V., Schisterman, E. F.,
1188 Slama, R., 2018. Within-Day, Between-Day, and Between-Week Variability of Urinary

1189 Concentrations of Phenol Biomarkers in Pregnant Women. *Environmental Health*
1190 *Perspectives*. 126, 37005-37005.

1191 Vervliet, P., Gys, C., Caballero-Casero, N., Covaci, A., 2019. Current-use of developers in
1192 thermal paper from 14 countries using liquid chromatography coupled to quadrupole
1193 time-of-flight mass spectrometry. *Toxicology*. 416, 54-61.

1194 Viel, J. F., Warembourg, C., Le Maner-Idrissi, G., Lacroix, A., Limon, G., Rouget, F., Monfort,
1195 C., Durand, G., Cordier, S., Chevrier, C., 2015. Pyrethroid insecticide exposure and
1196 cognitive developmental disabilities in children: The PELAGIE mother-child cohort.
1197 *Environment International*. 82, 69-75.

1198 Wang, L. M., Luo, D., Li, X., Hu, L. Q., Chen, J. X., Tu, Z. Z., Sun, B., Chen, H. G., Liu, L., Yu, M.,
1199 Li, Y. P., Pan, A., Messerlian, C., Mei, S. R., Wang, Y. X., 2021. Temporal variability of
1200 organophosphate flame retardant metabolites in spot, first morning, and 24-h urine
1201 samples among healthy adults. *Environ Res*. 196, 110373.

1202 Wang, X., Liu, Q., Zhong, W., Yang, L., Yang, J., Covaci, A., Zhu, L., 2020. Estimating renal and
1203 hepatic clearance rates of organophosphate esters in humans: Impacts of intrinsic
1204 metabolism and binding affinity with plasma proteins. *Environ Int*. 134, 105321.

1205 Wang, Y., Li, W., Martinez-Moral, M. P., Sun, H., Kannan, K., 2019a. Metabolites of
1206 organophosphate esters in urine from the United States: Concentrations, temporal
1207 variability, and exposure assessment. *Environ Int*. 122, 213-221.

1208 Wang, Y. X., Feng, W., Zeng, Q., Sun, Y., Wang, P., You, L., Yang, P., Huang, Z., Yu, S. L., Lu, W.
1209 Q., 2016. Variability of Metal Levels in Spot, First Morning, and 24-Hour Urine Samples
1210 over a 3-Month Period in Healthy Adult Chinese Men. *Environ Health Perspect*. 124, 468-
1211 76.

1212 Wang, Y. X., Liu, C., Shen, Y., Wang, Q., Pan, A., Yang, P., Chen, Y. J., Deng, Y. L., Lu, Q.,
1213 Cheng, L. M., Miao, X. P., Xu, S. Q., Lu, W. Q., Zeng, Q., 2019b. Urinary levels of bisphenol
1214 A, F and S and markers of oxidative stress among healthy adult men: Variability and
1215 association analysis. *Environ Int*. 123, 301-309.

1216 Watkins, D. J., Eliot, M., Sathyanarayana, S., Calafat, A. M., Yolton, K., Lanphear, B. P., Braun,
1217 J. M., 2014. Variability and predictors of urinary concentrations of phthalate metabolites
1218 during early childhood. *Environ Sci Technol*. 48, 8881-90.

1219 WHO, Safety of pyrethroids for public health use. 2005.

1220 WHO, WHO Guidelines for malaria. 2021.

1221 Wielgomas, B., Nahorski, W., Czarnowski, W., 2013. Urinary concentrations of pyrethroid
1222 metabolites in the convenience sample of an urban population of Northern Poland.
1223 *International journal of hygiene and environmental health*. 216, 295-300.

1224 Wong, F., de Wit, C. A., Newton, S. R., 2018. Concentrations and variability of
1225 organophosphate esters, halogenated flame retardants, and polybrominated diphenyl
1226 ethers in indoor and outdoor air in Stockholm, Sweden. *Environ Pollut*. 240, 514-522.

1227 Woodward, M. J., Obsekov, V., Jacobson, M. H., Kahn, L. G., Trasande, L., 2020. Phthalates
1228 and Sex Steroid Hormones Among Men From NHANES, 2013-2016. *J Clin Endocrinol*
1229 *Metab*. 105.

1230 Wormuth, M., Scheringer, M., Vollenweider, M., Hungerbuhler, K., 2006. What are the
1231 sources of exposure to eight frequently used phthalic acid esters in Europeans? *Risk Anal*.
1232 26, 803-24.

1233 Xu, F., Garcia-Bermejo, A., Malarvannan, G., Gomara, B., Neels, H., Covaci, A., 2015. Multi-
1234 contaminant analysis of organophosphate and halogenated flame retardants in food

1235 matrices using ultrasonication and vacuum assisted extraction, multi-stage cleanup and
1236 gas chromatography-mass spectrometry. *J Chromatogr A*. 1401, 33-41.

1237 Xu, F., Giovanoulis, G., van Waes, S., Padilla-Sanchez, J. A., Papadopoulou, E., Magner, J.,
1238 Haug, L. S., Neels, H., Covaci, A., 2016. Comprehensive Study of Human External Exposure
1239 to Organophosphate Flame Retardants via Air, Dust, and Hand Wipes: The Importance of
1240 Sampling and Assessment Strategy. *Environ Sci Technol*. 50, 7752-60.

1241 Yazdy, M. M., Coull, B. A., Gardiner, J. C., Aguiar, A., Calafat, A. M., Xiaoyun, Y., Schantz, S. L.,
1242 Korricks, S. A., 2018. A possible approach to improving the reproducibility of urinary
1243 concentrations of phthalate metabolites and phenols during pregnancy. *Journal of
1244 exposure science & environmental epidemiology*. 28, 448-460.

1245 Ye, M., Beach, J., Martin, J. W., Senthilselvan, A., 2016. Urinary concentrations of pyrethroid
1246 metabolites and its association with lung function in a Canadian general population.
1247 *Occupational and Environmental Medicine*. 73, 119-126.

1248 Ye, X., Wong, L. Y., Kramer, J., Zhou, X., Jia, T., Calafat, A. M., 2015. Urinary Concentrations of
1249 Bisphenol A and Three Other Bisphenols in Convenience Samples of U.S. Adults during
1250 2000-2014. *Environ Sci Technol*. 49, 11834-9.

1251 Yoshida, T., Mimura, M., Sakon, N., 2021. Estimating household exposure to pyrethroids and
1252 the relative contribution of inhalation pathway in a sample of Japanese children.
1253 *Environmental Science and Pollution Research* 2021 28:15. 28, 19310-19324.

1254 Zhang, R., Zhang, Q., Ma, L. Q., Cui, X., 2020. Effects of Food Constituents on Absorption and
1255 Bioaccessibility of Dietary Synthetic Phenolic Antioxidant by Caco-2 Cells. *J Agric Food
1256 Chem*. 68, 4670-4677.

1257 Zhou, L., Hiltcher, M., Gruber, D., Puttmann, W., 2017. Organophosphate flame retardants
1258 (OPFRs) in indoor and outdoor air in the Rhine/Main area, Germany: comparison of
1259 concentrations and distribution profiles in different microenvironments. *Environ Sci Pollut
1260 Res Int*. 24, 10992-11005.

1261